WO2006013399A1 - Pharmaceutical intermediates and a process for the preparation thereof - Google Patents

Pharmaceutical intermediates and a process for the preparation thereof Download PDF

Info

Publication number
WO2006013399A1
WO2006013399A1 PCT/HU2005/000067 HU2005000067W WO2006013399A1 WO 2006013399 A1 WO2006013399 A1 WO 2006013399A1 HU 2005000067 W HU2005000067 W HU 2005000067W WO 2006013399 A1 WO2006013399 A1 WO 2006013399A1
Authority
WO
WIPO (PCT)
Prior art keywords
ethyl
phenyl
methyl
hydrogen
chloro
Prior art date
Application number
PCT/HU2005/000067
Other languages
French (fr)
Inventor
József Barkóczy
István LING
József BÁLINT
Gabriella Egri
Violetta Kiss
Elemér Fogassy
Original Assignee
EGIS Gyógyszergyár Rt.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HU0401267A external-priority patent/HU0401267D0/en
Priority claimed from HU0500622A external-priority patent/HUP0500622A3/en
Application filed by EGIS Gyógyszergyár Rt. filed Critical EGIS Gyógyszergyár Rt.
Publication of WO2006013399A1 publication Critical patent/WO2006013399A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C07C215/38Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings with rings other than six-membered aromatic rings being part of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/31Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by at least three rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/40Halogenated unsaturated alcohols
    • C07C33/46Halogenated unsaturated alcohols containing only six-membered aromatic rings as cyclic parts
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00Ethers; Compounds having groups, groups or groups
    • C07C43/02Ethers
    • C07C43/20Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/62Halogen-containing esters
    • C07C69/63Halogen-containing esters of saturated acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/80Phthalic acid esters
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/003Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions
    • C12P41/004Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions by esterification of alcohol- or thiol groups in the enantiomers or the inverse reaction
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Definitions

  • the present invention relates to new pharmaceutical intermediates and a process for the preparation thereof.
  • Optically active aryl-isopropanols are important pharmaceutical intermediates. According to DE 2832604 steroid compounds are prepared in a stereoselective synthesis by using the corresponding enantiomeric aryl-isopropanol derivatives. In /. Am. Chem. Soc. (1995), 777, 12358-12359 the synthesis of talampanel is described; the key intermediate is also an enantiomeric aryl-isopropanol derivative. According to Bull. Soc. Chim. 130, 450-458 (1993) for the formation of the amino group of suitable stereo chemistry of (S)- phenfluramine as starting material an optically active aryl- isopropanol derivative is used.
  • Racemic aryl-isopropanols of the general Formula I of the present invention are known compounds.
  • the new racemic aryl-isopropanols of the general Formula I of the present invention are known compounds.
  • the new racemic aryl-isopropanols of the general Formula I of the present invention are known compounds.
  • the new racemic aryl-isopropanols of the general Formula I of the present invention are known compounds.
  • the new racemic aryl-isopropanols of the general Formula II of the present invention are known compounds.
  • the new racemic aryl-isopropanols of the general Formula I of the present invention are known compounds.
  • the new racemic aryl-isopropanols of the general Formula I of the present invention are known compounds.
  • the new racemic aryl-isopropanols of the general Formula II of the present invention are known compounds.
  • optically active aryl-isopropanols can be prepared by chemical or biochemical or enzyme catalyzed reactions.
  • optically active alcohol is prepared by reacting the lithium salt obtained by the reaction of optically active propylene oxide and 3-trifluoromethyl-bromo-benzene by using butyl-lithium at -78 0 C.
  • this process is not quite suitable for industrial scale manufacture because of the reactant and the extreme reaction conditions are used.
  • racemic alcohols are separated by means of enzyme catalyzed reaction of racemic O-acylated l-phenyl-2-propanol derivatives. Said enzymatic hydrolysis is carried out for a weak in a very diluted solution and the mixture of ester-alcohols obtained is separated by preparative thin-layer chromatography. The optically active l-phenyl-2-propanol obtained is converted into the corresponding optically active semiester without isolation.
  • racemic l-benzo[l,3]dioxol-5-yl-propane-2- ol into the enantiomers is described in Tetrahedron Asymmetry 14 333-337 (2003).
  • the essence of said process is that racemic aryl-isopropanol is acylated in the presence of a suitable lipase enzyme.
  • a (+)-rotating alcohol and a (-)-rotating acylated product are obtained.
  • acylating agent vinyl acetate is used in a hexane solution.
  • the acylated product and the alcohol used can be separated only by means of chromatography.
  • optically active acylated aryl- isopropanol derivative obtained in the reaction and the optically active aryl-isopropanol being still present in the reaction mixture have very similar solubility properties. Additionally, compounds of this type are generally oily substances having low melting point. This obvious separation method is, however, unsuitable for industrial scale manufacture.
  • the object of the present invention is the development of new enantiomeric aryl-isopropanol derivatives which enable the enantioselective synthesis of numerous new pharmaceutical active ingredients. It is a further object of the present invention to elaborate a process which eliminate the drawbacks of the methods described in prior art, can be performed in a reaction mixture of reasonable concentration, requires a relatively short reaction time, can be performed on industrial scale and provides an easy separation of the antipode forms of the process.
  • R 3 is hydrogen
  • R 1 and R 2 independently from each other stand for hydrogen, Ci -4 -alkyl, C 1-4 -alkoxy, aryloxy, aralkoxy, trifluoromethyl, cyano or halogen; or R and R together form methylenedioxy; with the proviso that at least one of symbols R 1 and R 2 is other than hydrogen; with the proviso that if R 1 and R 2 stand for alkoxy, one of said substituents is attached to position 2 of the phenyl ring; with the further proviso that if R 1 and R 2 together form methylenedioxy, said group together with the phenyl ring form l-benzo[l,3]dioxol-4-yl; or if one of symbols R 1 and R is cyano is attached to position 2, the other group is other than hydrogen or methoxy attached to position 3; or if one of symbols of R 1 and R 2 is hydrogen, the other is different from methoxy attached to position 2 or 3; or the chiral carbon
  • R is hydrogen
  • R and R independently from each other stand for hydrogen, Ci -4 -alkyl, Q ⁇ -alkoxy, aryloxy, aralkoxy, trifluoromethyl, cyano or halogen; or R 1 and R 2 together form methylenedioxy; with the proviso that at least one of symbols R 1 and R 2 is other than hydrogen; with the further proviso that if R 1 and R 2 are Ci -4 -alkoxy, one of said alkoxy groups is attached to position 2 of the phenyl
  • R 3 is Ci_ 4 -acyl
  • R 1 and R 2 independently from each other represent hydrogen, C 1-4 -alkyl, C 1-4 -alkoxy, aryloxy, aralkoxy, trifluoromethyl, cyano or halogen; or R 1 and R 2 together form methylenedioxy; with the proviso that at least one of symbols R 1 and R 2 is other than hydrogen; with the further proviso that if R 3 is acetyl and at least one of symbols of R and R is hydrogen, the substituent attached to position 4 of the phenyl ring is other than methoxy; or the chiral carbon atom is of ⁇ -configuration and
  • R 3 is Ci. 4 -acyl
  • R 1 and R 2 independently from each other stand for hydrogen, Ci_ 4 -alkyl, Ci_ 4 -alkoxy, aryloxy, aralkoxy, trifluoromethyl, cyano or halogen; or R 1 and R 2 together form methylenedioxy; with the proviso that at least one of symbols R 1 and R 2 is other than hydrogen; with the further proviso that if R 3 is acetyl and R 1 and R 2 together form methylenedioxy, said group together with the phenyl ring form l-benzo[l,3]dioxol-4-yl; or R 3 is acyl in which the group R 5 binds said acyl group with a further carboxy group; wherein
  • R 5 stands for substituted or unsubstituted alkenyl or aryl; with the proviso that if R 3 stands for phthalyl, one of symbols R 1 and R 2 represents methoxy attached to position 3 of the phenyl ring and the other is different from hydrogen or methoxy attached to position 4 of the phenyl ring; and salts of said racemic or optically active enantiomers formed with optically active bases with the exception of salts formed with optically active brucine as base and compounds of the general Formula I in which R 3 is phthalyl, one of symbols R 1 and R 2 is methoxy attached to position to 3 of the phenyl ring and the other is hydrogen or methoxy attached to position 4 of the phenyl ring.
  • R 1 and R 2 independently from each other stands for hydrogen, C ⁇ -alkyl, C 1 _ 4 -alkoxy, aryloxy, aralkoxy, trifluoromethyl, cyano or halogen; or R 1 and R 2 together form methylenedioxy
  • R 1 and R 2 independently from each other stands for hydrogen, C ⁇ -alkyl, C 1 _ 4 -alkoxy, aryloxy, aralkoxy, trifluoromethyl, cyano or halogen; or R 1 and R 2 together form methylenedioxy
  • R 1 and R 2 independently from each other stands for hydrogen, C 1-4 -alkyl, C 1-4 -alkoxy, aryloxy, aralkoxy, trifluoromethyl, cyano or halogen; or R 1 and R together form methylenedioxy
  • R 1 and R 2 independently from each other stands for hydrogen, C 1-4 -alkyl, C 1-4 -alkoxy, aryloxy, aralkoxy, trifluoromethyl, cyano or halogen; or R 1 and R together form methylenedioxy
  • R 1 and R 2 independently from each other stands for hydrogen, C 1-4 -alkyl, C 1-4 -alkoxy, aryloxy, aralkoxy, trifluoromethyl, cyano or halogen; or R 1 and R together form methylenedioxy
  • R 4 is C 1-4 - alkyl; R 1 and R 2 independently from each other stands for hydrogen, C 1-4 -alkyl, C 1-4 -alkoxy, aryloxy, aralkoxy, trifluoromethyl, cyano or halogen; or R 1 and R 2 together form methylenedioxy) converting the dicarboxylic acid derivative of the general Formula
  • R stands for alkyl, branched chain alkyl, alkenyl or aryl; R 1 and R 2 independently from each other stands for hydrogen, C 1-4 -alkyl, C 1-4 -alkoxy,. aralkoxy, trifluoromethyl, cyano or halogen; or R and R together form methylenedioxy
  • R stands for alkyl, branched chain alkyl, alkenyl or aryl; R 1 and R 2 independently from each other stands for hydrogen, C 1-4 -alkyl, C 1-4 -alkoxy,. aralkoxy, trifluoromethyl, cyano or halogen; or R and R together form methylenedioxy
  • into a salt by using an aqueous base in the presence of a water- insoluble solvent; thereafter separating the aqueous phase which contains the dicarboxylic acid derivative of the general Formula I/D from the organic phase which contains the acylated enantiomeric derivative of the general Formula I/C; thereafter
  • the present invention is based on the recognition that the separation of two enantiomers of aryl-isopropanols is high enantioselectivity can be carried out by using simple conventional extraction method of pharmaceutical industry by forming derivatives of the two enantiomers, one of said enantiomers being water-soluble and the other being soluble in water-immiscible solvents.
  • acylating the (+)-enantiomer aryl-isopropanol of the general Formula I/B with a dicarboxylic acid anhydride a semiester-semiacidic form beside the other enantiomer, namely the acylated derivative of the general Formula I/C.
  • the semiester-semiacid formed from the dextrorotatory enantiomer can be separated from the acylated derivative of the laevorotatory enantiomer by means of an alkaline aqueous and organic solvent extraction.
  • the salt formed from the semiester-semiacid of the general Formula I/D goes into the aqueous phase, whereby the acylated derivative of the general Formula I/C remains in the organic phase.
  • the phases are than worked up in a manner known per se.
  • the enantiomer-pure semiester-semiacid of the general Formula I/D is recovered from the aqueous phase.
  • On hydrolysing said compound one of the enantiomeric alcohols of the general Formula I/B is obtained, while the other enantiomeric alcohol is formed by subjecting the enantiomer of the general Formula I/C obtained from the organic phase to hydrolysis.
  • the aryl-isopropanol of the general Formula I/B having non-satisfactory optical purity is acylated with a dicarboxylic acid dihydrate in a manner known per se to yield the semiester-semiacid of the general Formula I/D; from said compound a salt is formed with an optically active base, the diastereomic salt is subjected to recrystallization and thereby a salt having the desired optical purity is obtained.
  • the semiester-semiacid of the general Formula I/D of satisfactory optical purity is set free from said salt and hydrolysis of the latter compound gives an aryl-isopropanol of the general Formula IfB having high optical purity.
  • the enzyme catalyzed reaction according to the present invention is carried out by using a lipase enzyme in an acylating solvent or a mixture of said acylating solvent and a further solvent.
  • acylating solvent preferably vinyl acetate or vinyl butylate, particularly vinyl acetate can be used.
  • One may also proceed by performing the reaction in a solvent of said acylating solvent formed with another solvent, or in the presence of a suitable solvent solution.
  • ether-type solvents particularly diethyl ether
  • saturated hydrocarbons preferably hexane or heptane
  • Acylation can also be performed in the presence of a phosphate buffer (pH 7.5).
  • lipase enzyme preferably Pseudomonas fhiorescens, Pseudomonas cepacia, Candida cylindracea, Candida antarctica or Mucor miehei lipase, particularly Pseudomonas cepacia lipase, particularly advantageously Amano® PS-C can be used.
  • the enzymatic reaction can be carried out at a temperature between 10-60 0 C, particularly 20-40 0 C, most advantageously at room
  • the reaction time is generally 4-72 hours, preferably 6-48 hours, the most advantageously 6-30 hours.
  • the mixture of the acylated compound of the general Formula I/C and the derivative of the general Formula I/B can be separated by formation of chemical derivatives.
  • a semiester-semiacid of the general Formula I/D is formed, whereby the acylated enantiomer of the general Formula I/C remains unchanged.
  • dicarboxylic acid derivative one can use derivatives of dicarboxylic acid containing alkyl, branched chain alkyl, substituted alkyl, alkenyl, substituted alkenyl or aryl groups, preferably derivatives of maleic acid, succinic acid or phthalic acid.
  • dicarboxylic acid anhydrates It is preferably to use dicarboxylic acid anhydrates.
  • Acylation of the compounds of the general Formula I/B can be carried out preferably in an inert solvent.
  • reaction medium preferably chlorinated hydrocarbon, acetonitrile, tetrahydrofurane, particularly dichloromethane can be used.
  • a catalyst preferably an organic base, particularly triethyl amine or diethyl amino-pyridine.
  • the semiester- semiacid derivative of the general Formula I/D is converted into a salt by using an aqueous base.
  • an alkali metal or an alkaline earth metal hydroxide, hydrogen carbonate or carbonate solution or suspension, particularly an alkali carbonate solution, most advantageously sodium carbonate solution can be used.
  • a two-phase reaction mixture is formed after the salt formation, whereby the organic phase contains the compound of the general Formula I/C and the aqueous phase contains the salt of the semiester-semiacid derivative of the general Formula I/D.
  • the two phases are separated and worked up by methods known per se. One may proceed by drying and evaporating the organic phase and, if necessary, purifying the compound of the general Formula I/C by distillation in vacuo.
  • the aqueous phase can be acidified and on adding a water non- miscible solvent, the organic acid solution of the semiester- semiacid of the general Formula I/D is obtained.
  • optically active organic amines can be used, e.g. (2 ⁇ -(+)-l-phenyl-ethyl-amine, ($-(-)- 1-phenyl- ethyl-amine, (+)-dehydroabiethyl-amine, quinine, (-)-l-(4- nitrophenyl)-2-amine- 1,3 -propanediol or ($-(+)-2-benzyl- amino-1-butanol.
  • Resolution is carried out in an organic solvent.
  • a dipolar aprotic solvent, ether- type solvent preferably ethyl acetate, acetone, diisopropyl ether, diethyl ether or a mixture of said solvents can be used.
  • the corresponding semiester-semiacid of the general Formula I/D is set free from the diastereomeric salt by using an aqueous acid which is then recovered from the reaction mixture by extraction. On evaporating the extract the semiester-semiacid of the general Formula I/D is obtained which is subjected to hydrolysis.
  • the reaction mixture of said hydrolysis step results in the optically pure aryl isopropanol of the general Formula IfB which can be purified by distillation, if necessary.
  • (+)- 1 -(4-fluoro-phenyl)-2-propanol (+)- 1 -(4-fluoro-phenyl)-2-propanol.
  • the essence of the present invention is the combination of an enzymatic route on the one hand and a chemical derivative- formation on the other.
  • the present invention provides a unique, completely unknown route for the separation of two enantiomers which is suitable for an industrial scale resolution.
  • optically pure derivatives can be separated by a simple method by using a conventional liquid-liquid extraction method
  • the enantioselective activity of the reaction can be influenced by choosing the reaction conditions, reaction time, temperature and the type of the lipase enzyme;
  • the enantiomer purity of the product obtained can be further improved with a significantly smaller reactant and apparatus need than the resolution of the complete amount of the racemic aryl-isopropanol;
  • the non-desired enantiomer pure antipode can be converted into the desired enantiomer by methods known from prior art in a simple way.
  • the present invention provides a new industrial scale process for the preparation of partially known and partially new optically active aryl-isopropanols.
  • Pseudomonas cepacia lipase To a solution of 35.00 g (194.23 mmoles) of 1- benzo[1.3]dioxol-5-yl-2-propanol in 175 ml of vinyl-acetate 10.50 g of Ps eudomonas cepacia lipase (Amano® PS-C) bond to a carrier are added. The mixture is stirred at room temperature for 6 hours, filtered, the enzyme is washed 4 times in 10 ml of vinyl-acetate each and the filtrate is evaporated in vacuo.
  • the reaction mixture gradually warms up, while its colour turns into dark brown.
  • the reaction mixture is heated to boiling for 5 minutes, cooled and washed once with 100 ml, once with 15 ml of 1.5 molar hydrochloric acid and twice with 15 ml of water each.
  • the dichloro-methane phase is extracted once with 125 ml and twice with 15 ml of a 1 molar sodium carbonate solution.
  • the aqueous layers are united and washed 3 times with 15 ml of dichloro-methane each.
  • the aqueous phase contains the sodium salt of (+)-2-(l- benzo[l .3]dioxol-5-yl)-l-methyl-ethyl-hydrogen-maleate.
  • the dichloro-methane phases are united, dried over sodium sulfate and the solvent is removed in vacuo. Thus 21.60 g (97.19
  • the reaction mixture gradually warms up, whereby its colour turns dark brown.
  • the reaction mixture is heated to boiling for 5 minutes, cooled, washed once with 10 ml, once with 3 ml of 1.5 molar hydrochloric acid and twice with 3 ml of water each.
  • the dichloro-methane layer is extracted once with 12.5 ml and twice with 3 ml of a 1 molar sodium-carbonate solution each.
  • the aqueous layers are united and washed 3 times with 3 ml of dichloro-methane each.
  • the aqueous phase contains the sodium salt of a (+)-2-(l- benzo[1.3]dioxol-5-yl)-l-methyl-ethyl-hydrogen-maleate.
  • the dichloro-methane are united, dried over sodium sulfate and the solvent is removed in vacuo. Thus 2.62 g (11.79 mmoles, yield 121.4 %) of (-)-2-(l-benzo[1.3]dioxol-5-yl)-l-methyl- ethyl-acetate are obtained.
  • the crystals are dissolved in 20 ml of hot ethyl-acetate and allowed to crystallize at room temperature for an hour.
  • the reaction mixture is heated to boiling for 5 minutes, then cooled, washed once in 100 ml and once with 10 ml of 1.5 molar hydrochloric acid and twice with 15 ml of water each.
  • the dichloro-methane phase is extracted once with 100 ml and twice with 5 ml of a 1 molar sodium-carbonate solution each.
  • the aqueous layers are united and washed 3 times with 15 ml of dichloro-methane each.
  • the reaction mixture warms up gradually and its colour turns dark brown.
  • the reaction mixture is heated to boiling for 5 minutes, cooled, washed once with 100 ml and once with 15 ml of 1.5 molar hydrochloric acid twice with 15 ml of water each.
  • the dichloro-methane phase is extracted once with 115 ml and twice with 15 ml of a 1 molar sodium carbonate solution.
  • the aqueous layers are united and washed 3 times with 15 ml of dichloro-methane each.
  • the aqueous phase contains the sodium salt of (+)-2-(4-chloro-phenyl)-l-methyl-ethyl- hydrogen-maleate.
  • the dichloro-methane phases are united, dried over sodium sulfate and the solvent is distilled off in vacuo.
  • 29.08 g (136.74 mmoles, 155.6 %) of (-)-l-(3- chloro-phenyl)-2-propil-acetate are obtained in the form of a yellow oil.
  • the crystals are dissolved in 10 ml of hot acetone. The solution is allowed to crystallize at 10 0 C for 10 hours. The crystals are filtered, washed twice with 5 ml of ethyl-acetate each and dried. Thus 3.85 g (9.82 mmoles, 27.1%) of white crystalline ( ⁇ ) -( ' - y ) -l-phenyl-ethyl-ammonium-[(-)-2-(4-chloro-phenyl)-l- methyl-ethyl-succinate] are obtained.
  • the reaction mixture gradually warms up, while its colour turns dark brown.
  • the reaction mixture is heated to boiling for 5 minutes, cooled, washed once with 100 ml and once with 10 ml of 1.5 molar hydrochloric acid and twice with 15 ml of water each.
  • a dichloro-methane layer is extracted once with 100 ml and twice with 5 ml of 1 molar sodium carbonate solution each.
  • the aqueous layers are united and washed 3 times with 15 ml of dichloro-methane each. [The aqueous
  • phase contains the sodium salt of the maleic acid semiester of (+)-l-(3,4-dichloro-phenyl)-2-propanol.]
  • the dichloro- methane layers are united, dried over sodium sulfate and the solvent is removed in vacuo.
  • 23.24 g (94.04 mmoles, 110.2 %) of (-)-2-(3,4-dichloro-phenyl)-l-methyl-ethyl-acetate are obtained in the form of a yellow oil.
  • the reaction mixture gradually warms up and its colour turns dark brown.
  • the reaction mixture is heated to boiling for 5 minutes, cooled, washed once with 85 ml and once with 10 ml of a 1.5 molar hydrochloric acid and twice with 15 ml of water.
  • the dichloro- methane phases are extracted once with 100 ml and twice with 5 ml of a 1 molar sodium carbonate solution.
  • the aqueous layers are united and washed 3 times with 15 ml of dichloro- methane each.
  • the aqueous phase contains the sodium salt of (+)-2-(3 ⁇ bromo-4-methoxy-phenyl)- 1 -methyl-ethyl-hydrogen- maleate.
  • the dichloro-methane phases are united, washed over sodium sulfate and the solvent is distilled off in vacuo.
  • 23.54 g (81.98 mmoles, 114.8 %) of (-)-2-(3-bromo-4- methoxy-phenyl)-l -methyl-ethyl-acetate are obtained in the form of a yellow oil.
  • the reaction mixture is heated to boiling for 5 minutes, cooled, washed once with 45 ml and once with 10 ml of 1.5 molar hydrochloric acid and twice with 10 ml of water each.
  • the dichloro-methane layer is extracted once with 20 ml and twice with 5 ml of 1 molar sodium carbonate solution each.
  • the aqueous layers are united and washed 3 times with 10 ml of dichloro-methane each.
  • the aqueous phase contains the sodium salt of (+)-2-(4- fluor-phenyl)-l-methyl-ethyl-hydrogen-maleate.]
  • the dichloro- methane phases are united, dried over sodium sulfate and the solvent is distilled off in vacuo.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention relates to pure enantiomer and in certain cases new racemic-isopropanol derivatives of the general Formula (I) and a process for the preparation thereof. The partly new and partly known compounds of the general Formula (I) are useful pharmaceutical intermediates. The substituent definition of symbols R1, R2 and R3 are as stated in the patent specification.

Description

PHARMACEUTICAL INTERMEDIATES AND A PROCESS FOR THE PREPARATION THEREOF
FIELD OF THE INVENTION
The present invention relates to new pharmaceutical intermediates and a process for the preparation thereof.
STATE OF THE ART
Optically active aryl-isopropanols are important pharmaceutical intermediates. According to DE 2832604 steroid compounds are prepared in a stereoselective synthesis by using the corresponding enantiomeric aryl-isopropanol derivatives. In /. Am. Chem. Soc. (1995), 777, 12358-12359 the synthesis of talampanel is described; the key intermediate is also an enantiomeric aryl-isopropanol derivative. According to Bull. Soc. Chim. 130, 450-458 (1993) for the formation of the amino group of suitable stereo chemistry of (S)- phenfluramine as starting material an optically active aryl- isopropanol derivative is used.
Racemic aryl-isopropanols of the general Formula I of the present invention are known compounds. The new racemic aryl-isopropanols of the general Formula
Figure imgf000003_0001
of the present invention can be prepared by methods analogous to those described in prior art. [HU 194550; J. Med. Chem., (1978), 21, 448-56].
According to prior art optically active aryl-isopropanols can be prepared by chemical or biochemical or enzyme catalyzed reactions.
InJ. Chem. Soc. 2987 (1956) and/. Am. Chem. Soc. 91, 996 (1969) chemical methods are described for the preparation of optically active l-phenyl-propane-2-ol. According to this process the racemic alcohol is converted into the semiester by reacting with phthalic anhydride in pyridine, whereupon the semiester obtained is reacted with brαcine in acetone, the precipitated diastereomic salt is recrystallized in 4-6 times and finally only one of the enantiomers is obtained in a yield of 19 %. This process is accompanied by several disadvantages. On the one hand the diastereomic salt is recrystallized several times which is disadvantageous economically and the yield obtained is very low. On the other hand even this low yield
Figure imgf000004_0001
necessities the use of a large quantity of resoluting agent detrimental to the health.
According to Tetrahedron Letters 34, 4145 (1993) l-(4-fluσro- phenyl)-propane-2-one is synthetized by using an enantioselective reduction; the reaction is carried out with borane in the presence of chiral oxazaborolidine catalyst. However, the optical purity of the alcohol obtained is not satisfactory; the enantiomer access is only 50 %. The product obtained can be used for stereoselective synthesis only after further purification and resolution. The authors have not even tried to isolate a pure enantiomeric product.
An enantioselective process is described in Bull. Soc. Chini. Fr. 130., 450 (1993) for the synthesis of optically active l-(3- trifluoromethyl-phenyl)-2-propanol. The optically active alcohol is prepared by reacting the lithium salt obtained by the reaction of optically active propylene oxide and 3-trifluoromethyl-bromo-benzene by using butyl-lithium at -780C. For economical and technological reasons, however, this process is not quite suitable for industrial scale manufacture because of the reactant and the extreme reaction conditions are used. In J. Am. Chem. Soc. (1995), UT3 12358-12359 the preparation of ($-l-benzo[l,3]dioxol-5-yl-propane-2-ol by- enzymatic reduction is described. The benzo[l,3]dioxol-5-yl- propane-2-one is converted into the dextrorotatory optically active alcohol by using a reducing enzyme occurring in yeast. However, the reaction requires a very large volume and there this process is uneconomical.
An other process also requiring large volumes is described in DE 2832602. The (S>3-methoxy-phenyl-2-ρroρanol and (S)- 3,5-dimethoxy-phenyl-2-propanol are prepared by subjecting the corresponding ketones to enzymatic reduction.
In J. Chem. Soc. Chem. Commun. 1277-1278 (1985) the preparation of (^-3-methoxy-phenyl-2-propanol is disclosed. However, the authors do not describe the details of the process.
According to Biosci. Biotechnol. Biochem. 58 (7), 1330 (1994) racemic alcohols are separated by means of enzyme catalyzed reaction of racemic O-acylated l-phenyl-2-propanol derivatives. Said enzymatic hydrolysis is carried out for a weak in a very diluted solution and the mixture of ester-alcohols obtained is separated by preparative thin-layer chromatography. The optically active l-phenyl-2-propanol obtained is converted into the corresponding optically active semiester without isolation.
The separation of racemic l-benzo[l,3]dioxol-5-yl-propane-2- ol into the enantiomers is described in Tetrahedron Asymmetry 14 333-337 (2003). The essence of said process is that racemic aryl-isopropanol is acylated in the presence of a suitable lipase enzyme. As a result of the enantioselective acylation a (+)-rotating alcohol and a (-)-rotating acylated product are obtained. As acylating agent vinyl acetate is used in a hexane solution. However, during working up of the reaction mixture the acylated product and the alcohol used can be separated only by means of chromatography. This is not surprising because the optically active acylated aryl- isopropanol derivative obtained in the reaction and the optically active aryl-isopropanol being still present in the reaction mixture have very similar solubility properties. Additionally, compounds of this type are generally oily substances having low melting point. This obvious separation method is, however, unsuitable for industrial scale manufacture.
Summarized, it can be stated that the known procedures have serious drawbacks. The materials and reactants used in the chemical synthesis are detrimental to the environment and their
Figure imgf000007_0001
enantioselectivity is in many cases unsatisfactory. The biologically based methods can be only carried out in very diluted solutions requiring large reaction volume. Prior art fails to describe industrial scale methods for the separation of end products having similar physical properties formed in the synthesis.
The object of the present invention is the development of new enantiomeric aryl-isopropanol derivatives which enable the enantioselective synthesis of numerous new pharmaceutical active ingredients. It is a further object of the present invention to elaborate a process which eliminate the drawbacks of the methods described in prior art, can be performed in a reaction mixture of reasonable concentration, requires a relatively short reaction time, can be performed on industrial scale and provides an easy separation of the antipode forms of the process.
The above objects are solved by the present invention.
SUMMARY OF THE INVENTION
According to the present invention there are provided compounds of the general Formula I in which the chiral carbon atom is of (^-configuration
Figure imgf000008_0001
[wherein
R3 is hydrogen;
R1 and R2 independently from each other stand for hydrogen, Ci-4-alkyl, C1-4-alkoxy, aryloxy, aralkoxy, trifluoromethyl, cyano or halogen; or R and R together form methylenedioxy; with the proviso that at least one of symbols R1 and R2 is other than hydrogen; with the proviso that if R1 and R2 stand for alkoxy, one of said substituents is attached to position 2 of the phenyl ring; with the further proviso that if R1 and R2 together form methylenedioxy, said group together with the phenyl ring form l-benzo[l,3]dioxol-4-yl; or if one of symbols R1 and R is cyano is attached to position 2, the other group is other than hydrogen or methoxy attached to position 3; or if one of symbols of R1 and R2 is hydrogen, the other is different from methoxy attached to position 2 or 3; or the chiral carbon atom is of (Rj-confϊguration and
R is hydrogen;
R and R independently from each other stand for hydrogen, Ci-4-alkyl, Q^-alkoxy, aryloxy, aralkoxy, trifluoromethyl, cyano or halogen; or R1 and R2 together form methylenedioxy; with the proviso that at least one of symbols R1 and R2 is other than hydrogen; with the further proviso that if R1 and R2 are Ci-4-alkoxy, one of said alkoxy groups is attached to position 2 of the phenyl
Figure imgf000009_0001
ring; with the further proviso that if R1 and R2 together form methylenedioxy, said group together with the phenyl ring form l-benzo[l,3]dioxol-4-yl; or if one of symbols R1 and R2 stands for trifluoromethyl attached to position 3 or fluorine attached to position 4, the other symbol is other than hydrogen; or the chiral carbon atom is of (^-configuration and
R3 is Ci_4-acyl;
R1 and R2 independently from each other represent hydrogen, C1-4-alkyl, C1-4-alkoxy, aryloxy, aralkoxy, trifluoromethyl, cyano or halogen; or R1 and R2 together form methylenedioxy; with the proviso that at least one of symbols R1 and R2 is other than hydrogen; with the further proviso that if R3 is acetyl and at least one of symbols of R and R is hydrogen, the substituent attached to position 4 of the phenyl ring is other than methoxy; or the chiral carbon atom is of ^-configuration and
R3 is Ci.4-acyl;
R1 and R2 independently from each other stand for hydrogen, Ci_4-alkyl, Ci_4-alkoxy, aryloxy, aralkoxy, trifluoromethyl, cyano or halogen; or R1 and R2 together form methylenedioxy; with the proviso that at least one of symbols R1 and R2 is other than hydrogen; with the further proviso that if R3 is acetyl and R1 and R2 together form methylenedioxy, said group together with the phenyl ring form l-benzo[l,3]dioxol-4-yl; or R3 is acyl in which the group R5 binds said acyl group with a further carboxy group; wherein
R5 stands for substituted or unsubstituted alkenyl or aryl; with the proviso that if R3 stands for phthalyl, one of symbols R1 and R2 represents methoxy attached to position 3 of the phenyl ring and the other is different from hydrogen or methoxy attached to position 4 of the phenyl ring; and salts of said racemic or optically active enantiomers formed with optically active bases with the exception of salts formed with optically active brucine as base and compounds of the general Formula I in which R3 is phthalyl, one of symbols R1 and R2 is methoxy attached to position to 3 of the phenyl ring and the other is hydrogen or methoxy attached to position 4 of the phenyl ring.
According to a further aspect of the present invention there is provided a process for the preparation of enantiomers of aryl- isopropanol derivatives of the general Formula I (wherein R3 is hydrogen; R1 and R2 independently from each other stand for hydrogen, C^-alkyl, Ci-4-alkoxy, aryloxy, aralkoxy, trifluoromethyl, cyano or halogen; or R1 and R2 together form
Figure imgf000011_0001
methylenedioxy) by subjecting the corresponding racemic alcohol of the general Formula
Figure imgf000011_0002
(wherein R1 and R2 independently from each other stands for hydrogen, C^-alkyl, C1_4-alkoxy, aryloxy, aralkoxy, trifluoromethyl, cyano or halogen; or R1 and R2 together form methylenedioxy) to enantioselective acylation in an enzyme catalyzed reaction; thereafter acylating the enantiomeric aryl- isopropanol of the general Formula
Figure imgf000011_0003
which remained unchanged under the conditions of the enzyme-catalyzed reaction (wherein R1 and R2 independently from each other stands for hydrogen, C1-4-alkyl, C1-4-alkoxy, aryloxy, aralkoxy, trifluoromethyl, cyano or halogen; or R1 and R together form methylenedioxy) with a dicarboxyiic acid derivative in the presence of an acylated enantiomer of the general Formula
I/C
Figure imgf000011_0004
Figure imgf000012_0001
formed in the enzyme catalyzed reaction (wherein R4 is C1-4- alkyl; R1 and R2 independently from each other stands for hydrogen, C1-4-alkyl, C1-4-alkoxy, aryloxy, aralkoxy, trifluoromethyl, cyano or halogen; or R1 and R2 together form methylenedioxy) converting the dicarboxylic acid derivative of the general Formula
Figure imgf000012_0002
(wherein R stands for alkyl, branched chain alkyl, alkenyl or aryl; R1 and R2 independently from each other stands for hydrogen, C1-4-alkyl, C1-4-alkoxy,. aralkoxy, trifluoromethyl, cyano or halogen; or R and R together form methylenedioxy) into a salt by using an aqueous base in the presence of a water- insoluble solvent; thereafter separating the aqueous phase which contains the dicarboxylic acid derivative of the general Formula I/D from the organic phase which contains the acylated enantiomeric derivative of the general Formula I/C; thereafter working up both phases by methods known per se to obtain the individual enantiomeric derivatives; and thereafter optionally converting said enantiomeric derivatives into other derivatives and/or purifying the same.
Figure imgf000013_0001
DETAILED DESCRIPTION OF THE INVENTION
The present invention is based on the recognition that the separation of two enantiomers of aryl-isopropanols is high enantioselectivity can be carried out by using simple conventional extraction method of pharmaceutical industry by forming derivatives of the two enantiomers, one of said enantiomers being water-soluble and the other being soluble in water-immiscible solvents.
On subjecting acylation a racemic compound of the general Formula I/A by methods known from prior art [Poppe-Novak: Selectiv Biocatalysis A Synthetic Approach, VCH Weinheim New York (1992)] in the presence of a lipase enzyme due to the kinetic control only the (-)-enantiomer is acylated to yield a derivative of the general Formula I/C, whereby the other (+)- enantiomer of the general Formula I/B remains in the reaction mixture in unchanged form. On acylating the (+)-enantiomer aryl-isopropanol of the general Formula I/B with a dicarboxylic acid anhydride a semiester-semiacidic form beside the other enantiomer, namely the acylated derivative of the general Formula I/C. The semiester-semiacid formed from the dextrorotatory enantiomer can be separated from the acylated derivative of the laevorotatory enantiomer by means of an alkaline aqueous and organic solvent extraction. The salt formed from the semiester-semiacid of the general Formula I/D goes into the aqueous phase, whereby the acylated derivative of the general Formula I/C remains in the organic phase.
The phases are than worked up in a manner known per se. The enantiomer-pure semiester-semiacid of the general Formula I/D is recovered from the aqueous phase. On hydrolysing said compound one of the enantiomeric alcohols of the general Formula I/B is obtained, while the other enantiomeric alcohol is formed by subjecting the enantiomer of the general Formula I/C obtained from the organic phase to hydrolysis.
If the purity of the separated enantiomers is not satisfactory, purification can be readily carried out by subjecting the salts of said dicarboxylic semiesters formed with a chiral base to resolution. Accordingly the aryl-isopropanol of the general Formula I/B having non-satisfactory optical purity is acylated with a dicarboxylic acid dihydrate in a manner known per se to yield the semiester-semiacid of the general Formula I/D; from said compound a salt is formed with an optically active base, the diastereomic salt is subjected to recrystallization and thereby a salt having the desired optical purity is obtained. The semiester-semiacid of the general Formula I/D of satisfactory optical purity is set free from said salt and hydrolysis of the latter compound gives an aryl-isopropanol of the general Formula IfB having high optical purity.
The enzyme catalyzed reaction according to the present invention is carried out by using a lipase enzyme in an acylating solvent or a mixture of said acylating solvent and a further solvent. As acylating solvent preferably vinyl acetate or vinyl butylate, particularly vinyl acetate can be used. One may also proceed by performing the reaction in a solvent of said acylating solvent formed with another solvent, or in the presence of a suitable solvent solution. As further solvent preferably ether-type solvents (particularly diethyl ether) or saturated hydrocarbons (preferably hexane or heptane) can be used. Acylation can also be performed in the presence of a phosphate buffer (pH 7.5). As lipase enzyme preferably Pseudomonas fhiorescens, Pseudomonas cepacia, Candida cylindracea, Candida antarctica or Mucor miehei lipase, particularly Pseudomonas cepacia lipase, particularly advantageously Amano® PS-C can be used. The enzymatic reaction can be carried out at a temperature between 10-600C, particularly 20-400C, most advantageously at room
Figure imgf000016_0001
temperature. The reaction time is generally 4-72 hours, preferably 6-48 hours, the most advantageously 6-30 hours.
The mixture of the acylated compound of the general Formula I/C and the derivative of the general Formula I/B can be separated by formation of chemical derivatives. On acylating with a dicarboxylic acid derivative from the compound of the general Formula I/B a semiester-semiacid of the general Formula I/D is formed, whereby the acylated enantiomer of the general Formula I/C remains unchanged. As dicarboxylic acid derivative one can use derivatives of dicarboxylic acid containing alkyl, branched chain alkyl, substituted alkyl, alkenyl, substituted alkenyl or aryl groups, preferably derivatives of maleic acid, succinic acid or phthalic acid. It is preferably to use dicarboxylic acid anhydrates. Acylation of the compounds of the general Formula I/B can be carried out preferably in an inert solvent. As reaction medium preferably chlorinated hydrocarbon, acetonitrile, tetrahydrofurane, particularly dichloromethane can be used. One can work in the presence of a catalyst, preferably an organic base, particularly triethyl amine or diethyl amino-pyridine. The semiester- semiacid derivative of the general Formula I/D is converted into a salt by using an aqueous base. In the reaction an alkali metal or an alkaline earth metal hydroxide, hydrogen carbonate or carbonate solution or suspension, particularly an alkali carbonate solution, most advantageously sodium carbonate solution can be used. A two-phase reaction mixture is formed after the salt formation, whereby the organic phase contains the compound of the general Formula I/C and the aqueous phase contains the salt of the semiester-semiacid derivative of the general Formula I/D. The two phases are separated and worked up by methods known per se. One may proceed by drying and evaporating the organic phase and, if necessary, purifying the compound of the general Formula I/C by distillation in vacuo. The aqueous phase can be acidified and on adding a water non- miscible solvent, the organic acid solution of the semiester- semiacid of the general Formula I/D is obtained.
On subjecting the compounds of the general Formulae I/C and I/D to hydrolysis the two enantiomeric alcohols of the general Formula I/B are obtained.
If the purity of the separated enantiomers is not satisfactory, further purification can be readily carried out by subjecting the salts of the dicarboxylic acid-semiesters formed with chiral bases to resolution.
As chiral base preferably optically active organic amines can be used, e.g. (2^-(+)-l-phenyl-ethyl-amine, ($-(-)- 1-phenyl- ethyl-amine, (+)-dehydroabiethyl-amine, quinine, (-)-l-(4- nitrophenyl)-2-amine- 1,3 -propanediol or ($-(+)-2-benzyl- amino-1-butanol. Resolution is carried out in an organic solvent. At reaction medium a dipolar aprotic solvent, ether- type solvent, preferably ethyl acetate, acetone, diisopropyl ether, diethyl ether or a mixture of said solvents can be used.
It is known that on crystallization from an inert solvent as a result of thermodynamical control one of the diastereomeric salts precipitates in crystalline form. The precipitated salt is separated by filtration. The filtered diastereomeric salt obtained in said stereoselective process contains the semiester of one of the optically active aryl isopropanol enantiomers, while the semiester of the other optically active aryl isopropanol enantiomer remains in the mother lye. If the optical purity of the aryl isopropanol enantiomer semiester component of the filtered diastereomeric salt is not satisfactory, it can be further purified by recrystallization.
The corresponding semiester-semiacid of the general Formula I/D is set free from the diastereomeric salt by using an aqueous acid which is then recovered from the reaction mixture by extraction. On evaporating the extract the semiester-semiacid of the general Formula I/D is obtained which is subjected to hydrolysis. The reaction mixture of said hydrolysis step results in the optically pure aryl isopropanol of the general Formula IfB which can be purified by distillation, if necessary.
According to a further feature of the present invention there are provided the following intermediates:
(±)_? (_)_, and (+)-2-(l-benzo[l,3]dioxol-5-yl)-l-methyl-ethyl- hydrogen-maleate,
(±)-, (-)-, and (+)-2-(l-benzo[l,3]dioxol-5-yl)-l-methyl-ethyl- hydrogen-succinate,
(±)-, (-)-, and (+)-2-(l-benzo[l,3]dioxol-5-yl)-l-methyl-ethyl- hydrogen-phthalate,
(S^-(9-phenyl-ethyl-ammonium-{(+)-2-(l-benzo[l,3]dioxol-5- yl)- 1 -methyl-ethyl-maleate} , fRj-f'+j-phenyl-ethyl-ammonium- {(+)-2-(l -benzo[ 1 ,3]dioxol-
5-yl)- 1 -methyl-ethyl-maleate} ,
CSJ-(9-phenyl-ethyl-ammonium- {(-)-2-(l -benzo[ 1 ,3]dioxol-5- yl)- 1 -methyl-ethyl-maleate} ,
^-f+j-phenyl-ethyl-ammonium- {(-)-2-(l-benzo[ 1 ,3]dioxol-5- yl)- 1 -methyl-ethyl-maleate} ,
(+)-dehydroabiethyl-ammonium- {(-)-2-(l -benzo[l ,3]dioxol-5- yl)- 1 -methyl-ethyl-maleate} ,
(±)-, (-)-, and (+)-2-(4-chloro-ρhenyl)-l-methyl-ethyl- hydrogen-maleate,
Figure imgf000020_0001
(±)-, (-)-, and (+)-2-(4-chloro-ρhenyl)-l-methyl-ethyl- hydrogen-succinate,
(±)-, (-)-, and (+)-2-(4-chloro-phenyl)-l-methyl-ethyl- hydrogen-phthalate,
(-)-2-(4-chloro-phenyl)- 1 -methyl-ethyl-acetate,
(+)- and (-)-l-(4-chloro-phenyl)-2-propanol,
(ϊ?j-f"+j-phenyl-ethyl-arnmonmm-[(-)-2-(4-chloro-phenyl)-l- methyl-ethyl-maleate],
(2?y)-^+J-phenyl-ethyl-anraionium-[(-)-2-(4-chloro-phenyl)-l- methyl-ethyl-succinate] , fSJ-(^-phenyl-ethyl-ammonium-[(-)-2-(4-chloro-phenyl)-l- methyl-ethyl-succinate] ,
(R)-f+j-phenyl-ethyl-ammonium-[(+)-2-(4-chloro-phenyl)- 1 - methyl-ethyl-maleate] ,
(^-f-y)-phenyl-ethyl-ammonium-[(+)-2-(4-chloro-phenyl)-l- methyl-ethyl-maleate],
(+)-dehydroabiethyl-ammonmm- [(+)-2-(4-chloro-phenyl)- 1 - methyl-ethyl-maleate] ,
(+)-dehydroabiethyl-ammonium- [(-)-2-(4-chloro-phenyl)- 1 - methyl-ethyl-maleate] ,
(7?j-^+j-phenyl-ethyl-ammonium-[(-)-2-(4-chloro-phenyl)-l- methyl-ethyl-phthalate] ,
(^)-(9-phenyl-ethyl-ammonium-[(-)-2-(4-chloro-phenyl)- 1 - methyl-ethyl-phthalate] ,
Figure imgf000021_0001
(+)-2-(4-chloro-phenyl)- 1 -methyl-ethyl-hydrogen-succinate quinine salt,
(-)-2-hydroxy- 1 -(hydroxy-methyl)-2-(4-nitro-phenyl)-ethyl- ammonium- [(+)-2-(4-chloro-phenyl)- 1 -methyl-ethyl- phthalate],
(±)-, (-)-, and (+)-2-(3-chloro-ρhenyl)-l-methyl-ethyl- hydrogen-maleate,
(±)-, (-)-, and (+)-2-(3-chloro-ρhenyl)-l-methyl-ethyl- hydrogen-succinate,
(±)-, (-)-, and (+)-2-(3-chloro-phenyl)-l-methyl-ethyl- hydrogen-phthalate,
(-)-2-(3 -chloro-phenyl)- 1 -methyl-ethyl-acetate,
(+)- and (-)-l-(3-chloro-phenyl)-2-propanol,
(+)-dehydroabiethyl-amnionium-[(+)-2-(3-chloro-phenyl)-l- methyl-ethyl— maleate] ,
(+)-dehydroabiethyl-ammonium-[(-)-2-(3-chloro-phenyl)-l- methyl-ethyl— maleate] ,
(Rj-f+/)-phenyl-ethyl-amtnonium-[(-)-2-(3-chloro-phenyl)-l- methyl-ethyl-maleate] ,
(^-(-)-phenyl-ethyl-ammonium-[(-)-2-(3 ,4-dichloro-phenyl)- 1 - methyl-ethyl-phtalate] ,
(±)-, (-)-, and (+)-2-(3 ,4-dichloro-phenyl)- 1-methyl-ethyl- hydrogen-maleate,
(±)-, (-)-, and (+)-2-(3,4-dichloro-phenyl)-l-methyl-ethyl- hydrogen-succinate, (±)-, (-)-, and (+)-2-(3,4-dichloro-phenyl)-l-methyl-ethyl- hydrogen-phthalate,
(-)-2-(3,4-dichloro-phenyl)- 1 -methyl-ethyl-acetate,
(+)- and (-)-l-(3,4-dichloro-phenyl)-2-propanol,
(RJ-^+j-phenyl-ethyl-ammonium-[(-)-2-(3,4-dichloro-phenyl)-
1 -methyl-ethyl-maleate] ,
(^?y)-(/+j-phenyl-ethyl-amnionium-[(+)-2-(3,4-dichloro-phenyl)-
1 -methyl-ethyl-phthalate],
(^-(9-phenyl-ethyl-animonium-[(-)-2-(3,4-dichloro-phenyl)-l- methyl-ethyl-succinate] ,
(^)-(9-phenyl-ethyl-amnionium- [(-)-2-(3 ,4-dichloro-phenyl)- 1 - methyl-ethyl-phthalate] ,
(+)-dehydroabiethyl-ammonium-[(+)-2-(3,4-dichloro-phenyl)-
1 -methyl-ethyl-maleate] ,
(+)-dehydroabiethyl-ammonium- [(+)-2-(3 ,4-dichloro-phenyl)-
1 -methyl-ethyl-succinate] ,
(±)-, (-)-, and (+)-2-(3-bromo-4-methoxy-phenyl)-l-methyl- ethyl-hydrogen-maleate,
(±)-5 (-)-, and (+)-2-(3-bromo-4-methoxy-phenyl)-l-methyl- ethyl-hydrogen-succinate,
(±)-, (-)-, and (+)-2-(3-bromo-4-methoxy-phenyl)-l-methyl- ethyl-hydrogen-phthalate,
(-)-2-(3-bromo-4-methoxy-phenyl)- 1 -methyl-ethyl-acetate,
(+)- and (-)-l-(3-bromo-4-methoxy-phenyl)-2-propanol, (+)-dehydroabiethyl- ammonium- [(-)-2-(3 -bromo-4-methoxy- phenyl)- 1 -methyl-ethyl-maleate] ,
(^Rj-f+j-phenyl-ethyl-ammonram-[(+)-2-(3-bromo-4-methoxy- phenyl)- 1 -methyl-ethyl-succinate] ,
(Ry)-f+/)-phenyl-ethyl-ammonium-[(-)-2-(3-bromo-4-methoxy- phenyl)- 1 -methyl-ethyl-phthalate],
(5^-(+)-benzyl-[l-(hydroxy-methyl)-propyl]-ammonium-[(-)-2-
(3-bromo-4-methoxy-phenyl)-l-methyl-ethyl-phthalate],
(±)-, (-)-, and (+)-2-(4-fluoro-ρhenyl)-l-methyl-ethyl- hydrogen-maleate,
(±)-, (-)-, and (+)-2-(4-fluoro-phenyl)-l-methyl-ethyl- hydrogen-succinate,
(±)-, (-)-, and (+)-2-(4-fluoro-ρhenyl)-l-methyl-ethyl- hydrogen-phthalate,
(-)-2-(4-fluoro-phenyl)- 1 -methyl-ethyl-acetate,
(+)- 1 -(4-fluoro-phenyl)-2-propanol.
The essence of the present invention is the combination of an enzymatic route on the one hand and a chemical derivative- formation on the other. Thus the present invention provides a unique, completely unknown route for the separation of two enantiomers which is suitable for an industrial scale resolution.
The present invention provides the following significant advantages:
Figure imgf000024_0001
- the enzymatic reaction is carried out under usual conditions of chemical industry in a relatively concentrated reaction mixture;
- the optically pure derivatives can be separated by a simple method by using a conventional liquid-liquid extraction method;
- neither extreme temperature conditions, nor special equipment is required;
- the enantioselective activity of the reaction can be influenced by choosing the reaction conditions, reaction time, temperature and the type of the lipase enzyme;
- the enantiomer purity of the product obtained can be further improved with a significantly smaller reactant and apparatus need than the resolution of the complete amount of the racemic aryl-isopropanol;
- the non-desired enantiomer pure antipode can be converted into the desired enantiomer by methods known from prior art in a simple way.
Summarized, the present invention provides a new industrial scale process for the preparation of partially known and partially new optically active aryl-isopropanols.
Figure imgf000025_0001
For example physical properties of several new optically active aryl-isopropanols according to our invention, some new salts of known optically active intermediers with chiral bases and some racemic compounds prepared as reference compounds are as follows:
Figure imgf000025_0002
Figure imgf000026_0001
Figure imgf000026_0002
Figure imgf000027_0001
Figure imgf000028_0001
Figure imgf000028_0002
Figure imgf000029_0001
Figure imgf000029_0002
Further details of the present invention are to be found in the following Examples without limiting the scope of protection to said Examples.
Example 1
Resolution of l-benzo[1.3]dioxol-5-yl-2-propanol by using
Pseudomonas cepacia lipase To a solution of 35.00 g (194.23 mmoles) of 1- benzo[1.3]dioxol-5-yl-2-propanol in 175 ml of vinyl-acetate 10.50 g of Ps eudomonas cepacia lipase (Amano® PS-C) bond to a carrier are added. The mixture is stirred at room temperature for 6 hours, filtered, the enzyme is washed 4 times in 10 ml of vinyl-acetate each and the filtrate is evaporated in vacuo. Thus 39.1 g of a mixture of (+)-l-benzo[1.3]dioxol-5- yl-2-propanol and (-)-2-(l-benzo[1.3]dioxol-5-yl)-l-methyl- ethyl-acetate are obtained in the form of a yellow oil.
The yellow oil obtained is dissolved in 100 ml of dichloro- methane, 17.50 ml (125.73 mmoles, d=0.727) of triethyl- amine, and in one portion 11.20 g (114.22 mmoles) of maleic anhydride are added. The reaction mixture gradually warms up, while its colour turns into dark brown. The reaction mixture is heated to boiling for 5 minutes, cooled and washed once with 100 ml, once with 15 ml of 1.5 molar hydrochloric acid and twice with 15 ml of water each. The dichloro-methane phase is extracted once with 125 ml and twice with 15 ml of a 1 molar sodium carbonate solution. The aqueous layers are united and washed 3 times with 15 ml of dichloro-methane each. [The aqueous phase contains the sodium salt of (+)-2-(l- benzo[l .3]dioxol-5-yl)-l-methyl-ethyl-hydrogen-maleate.] The dichloro-methane phases are united, dried over sodium sulfate and the solvent is removed in vacuo. Thus 21.60 g (97.19
Figure imgf000031_0001
inmoles, 100.1 %) of (-)-2-(l-benzo[1.3]dioxol-5-yl)-l-methyl- ethyl-acetate are obtained in the form of a yellow oil. The optical rotation is [α]D 25= -4.5° (c=2, chloroform).
21.40 g of the (-)-2-(l-benzo[1.3]dioxol-5-yl)-l-methyl-ethyl- acetate thus obtained, 30 ml of water, 15 ml of methanol and 6 g of sodium hydroxide are heated to boiling for 5 minutes, whereupon the methanol is distilled off in vacuo. The mixture is cooled and extracted once with 50 ml and 3 times with 15 ml of diethyl-ether. The ethereal phases are united, dried over sodium sulfate and the solvent is distilled off in vacuo. The residual oil (16.67 g) is subjected to distillation in vacuo. Thus 16.08 g (89.23 mmoles, 91.9 %) of Q-l-benzo[1.3]dioxol-5- yl-2-propanol are obtained in the form of an oil. The optical rotation is [α]D 25= -26.4° (c=2, chloroform), [α]365 25= -103,4° (c=2, chloroform).
To the aqueous phase containing the sodium salt of (+)-2-(l- benzo[l .3]dioxol-5-yl)-l-methyl-ethyl-hydrogen-maleate 30 ml of 37 % hydrochloric acid are added and it is extracted once in 50 ml and 3 times in 15 ml of dichloro-methane each. The dichloro-methane layers are united, dried over sodium sulfate and the solvent is distilled off in vacuo. Thus in the form of a brown oil 24.38 g (87.61 mmoles, yield 90.2 %) of (+)-2-(l- benzo[l .3]dioxol-5-yl)-l-methyl-ethyl-hydrogen-maleate are obtained. Optical purity: [α]D 25= +17.3° (c=2, chloroform).
23.98 g of (+)-2-(l-benzo[1.3]dioxol-5-yl)-l-methyl-ethyl- hydrogen-maleate are heated to boiling in a mixture of 36 ml of water and 12 g of sodium hydroxide for 1 minute. The mixture is cooled and extracted 4 times with 50 ml of diethyl- ether each. The ethereal phases are united, washed and dried over sodium sulfate and the solvent is distilled off in vacuo. The residual crude oil (14.55 g) is distilled off in vacuo. Thus 14.16 g (78.58 mmoles, 80.9 %) of oily (+)-l- benzo[1.3]dioxol-5-yl-2-propanol are obtained. Optical purity: [α]D 25= +32.2° (c=2, chloroform), [α]365 25= +124.1° (c=2, chloroform).
Example 2
Resolution of l-benzo[1.3]dioxol-5-yl-2-propanoI with
Candida antarctica lipase
To a solution of 3.50 g (19.42 mmoles) of l-benzo[1.3]dioxol- 5-yl-2-propanol in 10.5 ml of vinyl-acetate 300 mg of Candida antarctica lipase (Novozym® 435) bond to a carrier are added. The mixture is stirred at room temperature for 24 hours, filtered, the enzyme is washed 4 times in 1 ml of vinyl-acetate each and the filtrate is evaporated in vacuo. Thus 3.76 g of a mixture of (+)-l-benzo[1.3]dioxol-5-yl-2-propanol and (-)-2- (l-benzo[1.3]dioxol-5~yl)-l-methyl-ethyl-acetate are obtained in the form of a yellow oil.
The yellow oil thus obtained is dissolved in 10 ml of dichloro- methane, whereupon 1.75 ml (12.57 mmoles, d=0.727) of triethyl-amine and in one portion 1.12 g (11.42 mmoles) of maleic anhydride are added. The reaction mixture gradually warms up, whereby its colour turns dark brown. The reaction mixture is heated to boiling for 5 minutes, cooled, washed once with 10 ml, once with 3 ml of 1.5 molar hydrochloric acid and twice with 3 ml of water each. The dichloro-methane layer is extracted once with 12.5 ml and twice with 3 ml of a 1 molar sodium-carbonate solution each. The aqueous layers are united and washed 3 times with 3 ml of dichloro-methane each. [The aqueous phase contains the sodium salt of a (+)-2-(l- benzo[1.3]dioxol-5-yl)-l-methyl-ethyl-hydrogen-maleate.] The dichloro-methane are united, dried over sodium sulfate and the solvent is removed in vacuo. Thus 2.62 g (11.79 mmoles, yield 121.4 %) of (-)-2-(l-benzo[1.3]dioxol-5-yl)-l-methyl- ethyl-acetate are obtained. Optical rotation: [α]D 25= -2.9° (c=2, chloroform).
A mixture of the (-)-2-(l-benzo[1.3]dioxol-5-yl)-l-methyl- ethyl-acetate thus obtained, 5 ml of water, 3 ml of methanol and 0.6 g of sodium hydroxide is heated to boiling for 5 minutes, whereupon the methanol is distilled off in vacuo. The mixture is cooled and extracted 4 times with 10 ml of diethyl- ether each. The ethereal phases are united, dried over sodium sulfate and the solvent is removed in vacuo. Thus 2.03 g (11.26 mmoles, yield 116.0 %) of (-)-l-benzo[1.3]dioxol-5-yl- 2-propanol are obtained in the form of an oil. Optical rotation: [α]D 25= -16.6° (c=2, chloroform).
To the aqueous phase containing the sodium salt of the maleic acid semiester of (+)-l~benzo[1.3]dioxol-5-yl-2-propanol 3.5 ml of 37 % hydrochloric acid are added. The mixture is extracted 4 times with 10 ml of dichloro-methane each. The dichloro-methane phases are united, dried over sodium sulfate and the solvent is distilled off in vacuo. Thus 1.86 g (6.68 mmoles, yield 68.9 %) of (+)-2-(l-benzo[1.3]dioxol-5-yl)-l- methyl-ethyl-hydrogen-maleate are obtained in the form of a brown oil. Optical rotation: [α]D 25= +16.9° (c=2, chloroform).
A mixture of (+)-2-(l-benzo[1.3]dioxol-5-yl)-l-methyl-ethyl- hydrogen-maleate, 4 ml of water and 1.2 g of sodium hydroxide is heated to boiling for 1 minute. The reaction mixture is cooled and extracted 4 times with 10 ml of diethyl- ether each. The ethereal phases are united, dried over sodium sulfate and the solvent is removed in vacuo. Thus 1.09 g (6.05
Figure imgf000035_0001
mmoles, yield 62.3 %) of (+)-l-benzo[1.3]dioxol-5-yl-2- propanol are obtained in the form of an oil. Optical rotation: [α]D 25= +31.4° (c=2, chloroform).
Example 3
Enantiomer purification of (-)-l-benzo[1.3]dioxol-5-yl-2- propanol via the (2?j-(+)-l-phenyl-ethyl-ammoiiium salt of a maleic acid semiester
a) Preparation of(-)-2-(l-benzo[1.3]dioxol-5-yl)-l- methyl-ethyl-hydrogen-maleate
To a solution of 15.00 g (83.24 mmoles) of (-)-l- benzo[1.3]dioxol-5-yl-2-propanol {[α]D 25- -15.3° (c=2, chloroform)} in 60 ml of dichloro-methane 13.4 ml (96.26 mmoles, d=0.727) of triethyl-amine and in one portion 8.80 g (89.74 mmoles) of maleic anhydride are added. The reaction mixture warms gradually up, while its colour turns dark brown. The reaction mixture is stirred for 10 minutes, cooled, washed once with 80 ml, once with 20 ml of 1.5 molar hydrochloric acid and once with 20 ml of water. The dichloro-methane phase is dried over sodium sulfate and the solvent is distilled off in vacuo. Thus 24.14 g (86.76 mmoles, yield 97.7 %) of
Figure imgf000036_0001
(-)-2-(l-benzo[1.3]dioxol-5-yl)-l-methyl-ethyl-hydrogen- maleate are obtained in the form of an oily crystalline product. Optical rotation: [α]D 25= -11.0° (c=2, chloroform).
b) Enantiomer purification of (-)-2-(l-benzo[1.3]dioxol- 5-yl)-l-methyl-ethyl-hydrogen-maleate and the decomposition of the semiester
10.00 g (35.94 mmoles) of (-)-2-(l-benzo[1.3]dioxol-5-yl)-l- methyl-ethyl-hydrogen-maleate {[α]D 25= -11.0° (c=2, chloroform)} are dissolved in 10 ml in ethyl-acetate under heating. The dark brown solution is cooled to room temperature and 2.5 g (20.63 mmoles) of fR)-(+)-l-phenyl~ ethyl-amine and 30 ml diethyl-ether are added. The mixture is seeded with a small amount of diastereomic salt and allowed to stand at room temperature for 2 hours. The mixture is filtered, washed 4 times with 4 ml of diethyl-ether each and dried. Thus 6.78 g (16.97 mmoles, yield 47.2%) of almost white crystalline f'Ry)-f+j-l-phenyl-ethyl-ammonium-{(-)-2-(l-benzo[1.3]dioxol- 5-yl)-l-methyl-ethyl-maleate} are obtained.
The crystals are dissolved in 20 ml of hot ethyl-acetate and allowed to crystallize at room temperature for an hour. The
Figure imgf000037_0001
mixture is filtered, the crystals are washed 3 times with 2.5 ml of ethyl-acetate each and dried. Thus 6.08 g (15.22 mmoles, yield 42.3%) of almost white crystalline (Rj-f+j-1-phenyl- ethyl-ammonium-{(-)-2-(l-benzo[1.3]dioxol-5-yl)-l-methyl- ethyl-maleate} are obtained.
The crystals are dissolved in 18 ml of hot ethyl-acetate and allowed to crystallize at room temperature for an hour. The mixture is filtered, the crystals are washed 3 times with 2.5 ml of ethyl- acetate each and dried. Thus 5.27 g (13.19 mmoles, yield 36.7%) of almost white crystalline (R)-(+)-l-pheny[- ethyl-ammonium- {(-)-2-(l~benzo[l .3]dioxol-5-yl)-l-methyl- ethyl-maleate} . Optical rotation: [a]O 25= -6.1° (c=2, glacial acetic acid).
A mixture of 4.87g (12.19 mmoles) of the above salt, 40 ml of ethyl-acetate and 5 ml of 20% hydrochloric acid is stirred for 15 minutes. The layers of the clear, two-phase solution are separated, whereupon the ethyl-acetate phase is washed 3 times with 5 ml of 1.5 molar hydrochloric acid each, dried over sodium sulfate and the solvent is evaporated in vacuo. Thus 3.38 g (12.14 mmoles, yield 33.8%) of (-)-2-(l- benzo[l .3]dioxol-5-yl)-l-methyl-ethyl-hydrogen-maleate are obtained. Optical rotation: [α]D 25= -15.3° (c=2, chloroform).
Figure imgf000038_0001
A mixture of 2.98 g (7.46 mmoles) of the above semiester, 4.5 ml of water and 1.5 g of sodium hydroxide is heated to boiling for 1 minute. The reaction mixture is cooled and extracted 4 times with 10 ml of diethyl-ether each. The ethereal phases are united, dried over sodium sulfate and the solvent is removed in vacuo. Thus 1.68 g of an oil is obtained, which is subjected to distillation in vacuo. Thus 1.52 g (8.43 mmoles, yield 23.5 %) of oily (-)-l-benzo[1.3]dioxol-5-yl-2-propanol are obtained. Optical rotation: [a]O 25= -31.3° (c=2, chloroform).
Example 4
Resolution of l-(3-chloro-phenyl)-2-propanoI with
Pseudomonas cepacia lipase
To a solution of 35.00 g (205.11 mmoles) of l-(3-chloro- phenyl)-2-propanol in 105 ml of vinyl-acetate 3.00 g of Pseudomonas cepacia lipase (Amano® PS-C) bond to a carrier are added. The mixture is stirred at room temperature for 36 hours, filtered, the enzyme is washed 4 times with 10 ml of vinyl-acetate each and the filtrate is evaporated in vacuo. Thus 41.48 g of a mixture of (+)-l-(3-chloro-phenyl)-2-propanol and a (-)-2-(3-chloro-phenyl)-l -methyl-ethyl-acetate are obtained in the form of a yellow oil. The yellow oil thus obtained is dissolved in 100 ml dichloro- methane, whereupon 17.5 ml (125.73 mmoles, $=0,727) of triethyl-amine and in one portion 10.00 g (101.98 mmoles) of maleic anhydride are added. The reaction mixture gradually warms up, while its colour turns dark brown. The reaction mixture is heated to boiling for 5 minutes, then cooled, washed once in 100 ml and once with 10 ml of 1.5 molar hydrochloric acid and twice with 15 ml of water each. The dichloro-methane phase is extracted once with 100 ml and twice with 5 ml of a 1 molar sodium-carbonate solution each. The aqueous layers are united and washed 3 times with 15 ml of dichloro-methane each. [The aqueous layer contains the sodium salt of (+)-2-(3- chloro-phenyl)- 1 -methyl-ethyl-hydrogen-maleate.] The dichloro-methane phases are united, dried over sodium sulfate and the solvent is removed in vacuo. Thus 26.1 g (122.72 mmoles, yield 119.7 %) of (-)-2-(3-chloro-phenyl)-l -methyl- ethyl-acetate are obtained in the form of a yellow oil. Optical rotation: [α]D 25= -3.0° (c=2, chloroform).
A mixture of 25.80 g of (-)-2-(3-chloro-phenyl)-l -methyl- ethyl-acetate thus obtained, 15 ml of water, 25 ml of methanol and 7 g of sodium hydroxide is heated to boiling for 5 minutes, whereupon the methanol is removed in vacuo. The mixture is cooled and extracted once with 50 ml and 3 times with 15 ml of diethyl-ether each. The ethereal phases are united, dried over sodium sulfate and the solvent is distilled off in vacuo. The residual oil (21.25 g) is subjected to distillation in vacuo. Thus 20.33 g (l 19.14 mmoles, 116.2 %) of oily (-)-l-(3- chloro-phenyl)-2-propanol are obtained. Optical rotation: [α]D 25= -19.8° (c=2, chloroform).
To the aqueous phase containing the sodium salt of (+)-2-(3- chloro-phenyl)-l-methyl-ethyl-hydrogen-maleate 50 ml of 20 % hydrochloric acid are added. The mixture is extracted, once with 50 ml and 3 times with 15 ml of dichloro-methane each. The dichloro-methane phases are united, dried over sodium sulfate and the solvent is distilled off in vacuo. Thus 20.82 g (77.49 mmoles, 75.6 %) of (+)-2-(3-chloro-phenyl)-l-methyl- ethyl-hydrogen-maleate are obtained in the form of a brown oil. Optical rotation: [α]D 25= +14.2° (c=2, chloroform).
A mixture of 20.52 g of (+)-2-(3-chloro-phenyl)-l-methyl- ethyl-hydrogen-maleate, 60 ml of water and 8 g of sodium hydroxide is heated to boiling for 1 minute. The reaction mixture is cooled and extracted 4 times with 30 ml of diethyl- ether each. The ethereal phases are united, dried over sodium sulfate and the solvent is removed in vacuo. Thus 12.42 g of an oil are obtained which is subjected to distillation in vacuo. Thus 11.73 g (68.74 mmoles, 67.0 %) of oily (+)-l-(3-chlσro- phenyl)-2-propanol are obtained. Optical rotation: [α]D = +34.4° (c=2, chloroform).
Example 5
Enantiomer purification of (-)-l-(3-chIoro-phenyl)-2- propanol via the (+)-dehydroabiethyI-ammonium salt of the maleic acid semiester
a) Preparation of(-)-2-(3-chloro-phenyl)-l-methyl-ethyl- hydrogen-maleate
A mixture of 20.33 g (119.14 mmoles, [α]D 25= -19.8° (c=2, chloroform)) of (-)-l-(3-chloro-phenyl)-2-propanol, 80 ml of dichloro-methane, 18.50 ml of triethyl-amine (132.91 mmoles) and 12.50 g (127.47 mmoles) of maleic acid anhydride is heated to boiling for 10 minutes. The reaction mixture is cooled, washed once with 100 ml and once with 10 ml of 1.5 molar hydrochloric acid and once with 20 ml of water, dried over sodium sulfate and the solvent is distilled off in vacuo. Thus 32.01 g (119.13 mmoles, 100.0%) of (-)-2-(3-chloro- phenyl)-l-methyl-ethyl-hydrogen-maleate are obtained in the form of a dark brown oil. Optical rotation: [α]D 25= -8.3° (c=2, chloroform). b) Enantiomer purification of (-)-2-(3-chloro-phenyl)-l- methyl-ethyl-hydrogen-maleate and decomposition of the semiester
To a solution of 16.00 g (59.54 mmoles) of (-)-2-(3-chloro- ρhenyl)-l-methyl-ethyl-hydrogen-maleate {[α]D 25= -8.3° (c=2, chloroform)} and 80 ml of ethyl-acetate 28.0 g (technical grade, 60 %, 59.5 mmoles) of (+)-dehydroabiethyl-amine are added. The clear solution is seeded, allowed to crystallize for 10 hours, filtered, washed 5 times with 5 ml of ethyl-acetate each and dried. Thus 13.13 g (23.69 mmoles, 39.8%) of (+)- dehydroabiethyl-ammonium-[(-)-2-(3-chloro-phenyl)- 1 - methyl-ethyl-maleate are obtained.
The salt thus obtained is dissolved in 350 ml of hot acetone and the solution to evaporated to 86 g. The mixture is allowed crystallize at room temperature for 1 hour. After filtration the crystals are washed 5 times with 5 ml of ethyl-acetate each and dried. Thus 10.20 g (18.40 mmoles, 30.9%) of (+)- dehydroabiethyl-ammonium- [(-)-2-(3 -chloro-phenyl)- 1 - methyl-ethyl-maleate] are obtained.
10.20 g of (+)-dehydroabiethyl-ammonium-[(-)-2-(3-chloro- phenyl)-l -methyl-ethyl-maleate] are dissolved in 300 ml of hot acetone. The solution is evaporated to 63 g. The mixture is allowed to crystallize at room temperature for 1 hour, filtered, the crystals are washed 5 times with 5 ml of ethyl-acetate each and dried. Thus 7.97 g (14.38 mmoles, 24.2%) of (+)- dehydroabiethyl-ammonium-[(-)-2-(3-chloro-phenyl)- 1 - methyl-ethyl-maleate] are obtained. Optical rotation: [ccfo — +10.9° (c=2, acetic acid). Mp.: 140-1430C.
7.97 g of the salt thus obtained are dissolved in 25 ml of methanol, whereupon a solution of 0.80 g of sodium hydroxide in 5 ml of water and thereafter 100 ml of water are added. The reaction mixture is extracted 3 times with 30 ml of dichloro- methane each, acidified with 3 ml of 37 % hydrochloric acid and extracted 4 times with 20 ml of dichloro-methane each. The dichloro-methane phases are united, dried over sodium sulfate and the solvent is removed in vacuo. Thus 3.34 g (12.43 mmoles, 20.9 %) of (-)-2-(3-chloro-phenyl)-l-methyl- ethyl-hydrogen-maleate are obtained in the form of an oil.
3.34 g of (-)-2-(3-chloro-phenyl)-l-memyl-ethyl-hydrogen- maleate are dissolved in a mixture of 2.5 g sodium hydroxide and 6 ml of water and heated to boiling for 1 minute. The reaction mixture is cooled, extracted 4 times with 20 ml of diethyl-ether each. The ethereal phases are united, dried over sodium sulfate and the solvent is distilled off in vacuo. The residual crude oil (2.04 g) is distilled off in vacuo. Thus 1.82 g
Figure imgf000044_0001
(10.67 mmoles, 17.9 %) of (-)-l-(3-chloro-ρhenyl)-2-ρropanol a arree o obbttaaiinneedd.. Optical rotation: [α]D 25=: -33.8° (c=2, chloroform).
Example 6
Resolution of l-(4-chloro-phenyI)-2-propanol with
Pseudomonas cepacia lipase
To a solution of 30.00 g (175.81 mmoles) of l-(4-chloro- phenyl)-2-propanol in 150 ml of vinyl-acetate 9.00 g Pseudomonas cepacia lipase (Amano® PS-C) bond to a carrier are added. The mixture is stirred at room temperature for 48 hours, filtered, the enzyme is washed 4 times with 10 ml of vinyl-acetate each and the filtrate is evaporated in vacuo. Thus 37.71 g of a mixture of (+)-l-(4-chloro-phenyl)-2-propanol and (-)-2-(4-chloro-phenyl)-l -methyl-ethyl-acetate are obtained in the form of a yellow oil.
The yellow oil thus obtained is dissolved in 100 ml of dichloro-methane, whereupon 15.9 ml (114.23 mmoles, d=0.727) of triethyl-amine and in one portion 10.20 g (104.02 mmoles) maleic anhydride are added. The reaction mixture warms up gradually and its colour turns dark brown. The reaction mixture is heated to boiling for 5 minutes, cooled, washed once with 100 ml and once with 15 ml of 1.5 molar hydrochloric acid twice with 15 ml of water each. The dichloro-methane phase is extracted once with 115 ml and twice with 15 ml of a 1 molar sodium carbonate solution. The aqueous layers are united and washed 3 times with 15 ml of dichloro-methane each. [The aqueous phase contains the sodium salt of (+)-2-(4-chloro-phenyl)-l-methyl-ethyl- hydrogen-maleate.] The dichloro-methane phases are united, dried over sodium sulfate and the solvent is distilled off in vacuo. Thus 29.08 g (136.74 mmoles, 155.6 %) of (-)-l-(3- chloro-phenyl)-2-propil-acetate are obtained in the form of a yellow oil. Optical rotation : [α]D 25= -2.6° (c=2, chloroform).
A mixture of the (-)-2-(4-chloro-phenyl)-l -methyl-ethyl- acetate thus obtained, 45 ml of water, 20 ml of methanol and 10 g of sodium hydroxide is heated to boiling for 5 minutes. The methanol is distilled off in vacuo. The residue is cooled and extracted once with 50 ml and 3 times with 15 ml of diethyl-ether each. The ethereal phases are united, dried over sodium sulfate and the solvent is distilled off in vacuo. The residual oil (23.25 g) is subjected to distillation in vacuo. Thus 21.97 g (128.75 mmoles, 146.5 %) of (-)-l-(4-chloro-phenyl> 2-propanol are obtained. Optical rotation: [α]D 25= -8.6° {c-2, chloroform). To the aqueous phase containing the sodium salt of (+)-2-(4- chloro-phenyl)-l-methyl-ethyl-hydrogen-maleate 60 ml of 20 % hydrochloric acid are added and the mixture is extracted once with 50 ml and 3 times with 15 ml of dichloro-methane each. The dichloro-methane phases are united, dried over sodium sulfate and the solvent is distilled off in vacuo. Thus 10.16 g (37.81 mmoles, 43.0 %) of (-)-2-(4-chloro-phenyl)-l- methyl-ethyl-hydrogen-maleate are obtained in the form of a brown oil. Optical rotation [α]D 25= +14.2° (c=2, chloroform).
A mixture of 9.76 g (+)-2-(4-chloro-phenyl)-l-methyl-ethyl- hydrogen-maleate thus obtained, 25 ml of water and 5 g of sodium hydroxide is heated to boiling for 1 minutes. The reaction mixture is cooled and extracted 4 times with 10 ml of diethyl-ether each. The ethereal phases are united, dried over sodium sulfate and the solvent is distilled off in vacuo. The residual oil (5.92 g) is distilled off in vacuo. Thus 5.73 g (33.58 mmoles, 38.2 %) of (+)-l-(4-chloro-phenyl)-2-ρroρanol are obtained in the form of an oil. Optical rotation: [α]D 25= +31.2° (c=2, chloroform). Example 7
Enantiomer purification of (-)-l-(4-chloro-phenyl)-2- propanol via the fφ-(-)-l-phenyI-ethyl-ammonium salt of the succinic acid semiester
a) Preparation of(-)-2-(4-chloro-phenyl)-l-methyl-ethyl- hydrogen-succinate
A mixture of 6.25 g (36.63 mmoles) of (-)-l-(4-chloro- ρhenyl)-2-proρanol {[α]D 25= -16.2° (c=2, chloroform)} 30 ml of dichloro-methane, 5.7 ml of triethyl-amine (40.96 mmoles), a catalytic amount of N,N-dimethylamino-pyridine and 4.00 g (39.97 mmoles) of succinic acid anhydride is heated to boiling for 1 hour. The reaction mixture is cooled, washed once with 35 ml and once with 10 ml of 1.5 molar hydrochloric acid and once with 20 ml of water, dried over sodium sulfate and the solvent is removed in vacuo. Thus 9.83 g (36.31 mmoles, 99.1 %) of (-)-2-(4-chloro-ρhenyl)- 1 -methyl-ethyl-hydrogen- succinate are obtained in the form of a yellow oil. Optical rotation: [α]D 25= -1.4° (c=2, chloroform). b) Enantiomer purification of (-)-2-(4-chloro-phenyl)-l- methyl-ethyl-hydrogen-sucdnate and decomposition of the semiester
9.83 g (36.31 mmoles) of (-)-2-(4-chloro-phenyl)-l-methyl- ethyl-hydrogen-succinate {[α]D 25= -1.4° (c=2, chloroform)} are dissolved in 10 ml of acetone. The solution 4.40 g (36.31 mmoles) of (^-('-j-phenyl-ethylamine are added, the solution is seeded and allowed to crystallize at 10 0C for 2 hours. The crystals are filtered, washed twice with 5 ml of ethyl-acetate and dried. Thus 4.67 g (11.92 mmoles, 32.8%) of white crystalline (S)-(-)- l-phenyl-ethyl-ammonium-[(-)-2-(4-chloro- phenyl)-l-methyl-ethyl-succinate] are obtained.
The crystals are dissolved in 10 ml of hot acetone. The solution is allowed to crystallize at 10 0C for 10 hours. The crystals are filtered, washed twice with 5 ml of ethyl-acetate each and dried. Thus 3.85 g (9.82 mmoles, 27.1%) of white crystalline (^)-('-y )-l-phenyl-ethyl-ammonium-[(-)-2-(4-chloro-phenyl)-l- methyl-ethyl-succinate] are obtained.
The crystals are dissolved in 10 ml of hot acetone and the solution is allowed to crystallize -10 0C for 2 hours. The crystals are filtered, washed twice with 5 ml of ethyl-acetate each and dried. Thus 3,48 g (8.88 mmoles, 24.5%) of white crystalline (^)-(9-l-phenyl-ethyl-ammonium-[(-)-2-(4-chloro- phenyl)-l-methyl-ethyl-succinate] are obtained. Optical rotation: [α]D 25= -4.3° (c=2, methanol). Mp.: 113-115 0C.
The crystals are suspended in 30 ml of ethyl-acetate, washed 3 times with 10 ml of 1.5 molar hydrochloric acid each and once with 20 ml of water, dried over sodium sulfate and the solvent is removed in vacuo. Thus 2.25 g (8.31 mmoles, 22.9 %) of (-)-2-(4-chloro-phenyl)- 1 -methyl-ethyl-hydrogen-succinate are obtained in the form of a yellow oil. Optical rotation: [α]o = -2.7° (c=2, chloroform).
A mixture of (-)-2-(4-chloro-phenyl)-l-methyl-ethyl-hydrogen- succinate thus obtained, 4.5 ml of water and 1.5 g of sodium hydroxide is heated to boiling for 1 minute. The reaction mixture is cooled and extracted 4 times with 10 ml of diethyl- ether each. The ethereal phases are united, dried over sodium sulfate and the solvent is removed in vacuo. The residual oil (1.44 g) is subjected to distillation in vacuo. Thus 1.27 g (7.44 mmoles, 20.5 %) of (-)-l-(4-chloro-phenyl)-2-propanol are obtained in the form of a crystalline oil. Optical rotation: [α]D 25= -31.2° (c=2, chloroform).
Figure imgf000050_0001
Example 8
Resolution of l-(3,4-dichloro-phenyI)-2-propanol with
Pseudomonas cepacia lipase
To a solution of 35.00 g (170.67 mmoles) of l-(3,4-dichloro- phenyl)-2-propanol and 105 ml of vinyl-acetate 3.00 g of Pseudomonas cepacia lipase (Amano® PS-C) bond to a carrier are added. The reaction mixture is stirred at room temperature for 30 hours, filtered, the enzyme is washed 4 times with 10 ml of vinyl-acetate each and the filtrate is evaporated in vacuo. Thus 39.82 g of a mixture of (+)-l-(3,4-dichloro-ρhenyl)-2- propanol and (-)-2-(3,4-dichloro-phenyl)-l -methyl-ethyl- acetate are obtained in the form of a yellow oil.
The oil is dissolved in 100 ml of dichloro-methane, whereupon 14.5 ml (104.42 mmoles, d=0.727) of triethyl-amine and in one portion 8.50 g (86.73 mmoles) of maleic anhydride are added. The reaction mixture gradually warms up, while its colour turns dark brown. The reaction mixture is heated to boiling for 5 minutes, cooled, washed once with 100 ml and once with 10 ml of 1.5 molar hydrochloric acid and twice with 15 ml of water each. A dichloro-methane layer is extracted once with 100 ml and twice with 5 ml of 1 molar sodium carbonate solution each. The aqueous layers are united and washed 3 times with 15 ml of dichloro-methane each. [The aqueous
Figure imgf000051_0001
phase contains the sodium salt of the maleic acid semiester of (+)-l-(3,4-dichloro-phenyl)-2-propanol.] The dichloro- methane layers are united, dried over sodium sulfate and the solvent is removed in vacuo. Thus 23.24 g (94.04 mmoles, 110.2 %) of (-)-2-(3,4-dichloro-phenyl)-l-methyl-ethyl-acetate are obtained in the form of a yellow oil. Optical rotation: [α]D 25= -2.9° (c=2, chloroform).
A mixture of 23.04 g of (-)-2-(3,4-dichloro-ρhenyl)-l -methyl- ethyl-acetate thus obtained, 15 ml of water, 25 ml of methanol and 5.5 g of sodium hydroxide is heated to boiling for 5 minutes whereupon the methanol is distilled off in vacuo. The residue is cooled and extracted once with 50 ml and 3 times with 15 ml of diethyl-ether each. The ethereal phases are united, dried over sodium sulfate and the solvent is distilled off in vacuo. The residual oil (19.06 g) is subjected to distillation in vacuo. Thus 18.70 g (91.18 mmoles, 106.8 %) of (-)-l-(3,4- dichloro-phenyl)-2-propanol are obtained in the form of an oil. Optical rotation: [α]D 25= -18.8° (c=2, chloroform).
To the aqueous phase containing the sodium salt of (+)-2-(3,4- dichloro-phenyl)-l-methyl-ethyl-hydrogen-maleate 50 ml of 20 % hydrochloric acid are added. The reaction mixture is extracted once with 50 ml and 3 times with 15 ml of dichloro- methane each. The dichloro-methane phases are united, dried over sodium sulfate and the solvent is distilled off in vacuo. Thus 20.24 g (66.77 mmoles, 78.2 %) of (+)-2-(3,4-dichloro- phenyl)-l-methyl-ethyl-hydrogen-maleate are obtained in the form of a brown oil. Optical rotation: [OL]Ό 25= +8.5° (c=2, chloroform).
A mixture of 20.4 g of the (+)-2-(3,4-dichloro-ρhenyl)-l- methyl-ethyl-hydrogen-maleate thus obtained, 60 ml of water and 7 g of sodium hydroxide is heated to boiling for 1 minute. The reaction mixture is cooled and extracted 4 times with 30 ml of diethyl-ether each. The ethereal phases are united, dried over sodium sulfate and the solvent is distilled off in vacuo. The residual oil (13.07 g) is subjected to distillation in vacuo. Thus 12.13 g (59.16 mmoles, 69.2 %) of (+)-l-(3,4-dichloro- phenyl)-2-propanol are obtained in the form of an oil. Optical rotation : [α]D 25= +28.8° (c=2, chloroform). On standing the oil is solidified, mp.: 48-520C.
Examp ■Λlae. 9
Enantiomer purification of (-)-l-(3,4-dichloro-phenyl)-2- propanol via the $H-)-l-phenyl-ethyl-ammonium saIt of the phthalic acid semiester
a) Preparation of(-)-2-(3,4-dichloro-phenyl)-l-methyl- ethyl-hydrogen-phthalate A mixture of 7.10 g (34.62 mmoles) of (-)-l-(3,4-dichloro- ρhenyl)-2-propanol {[α]D 25= -18.8° (c=2, chloroform)}, 20 ml of dichloro-methane 5.50 ml of triethyl- amine (39.54 mmoles), a catalytic amount of N,N-dimethyl-amino-pyridine and 5.3O g (35.78 mmoles) of phthalic anhydride is heated to boiling for an hour. The reaction mixture is cooled, washed once with 30 ml and once with 10 ml of 1.5 molar hydrochloric acid each and once with 20 ml of water, dried over sodium sulfate and the solvent is removed in vacuo. Thus 12.19 g (34.51 mmoles, 99.7%) of (-)-2-(3,4-dichloro-phenyl)-l-methyl-ethyl- hydrogen-phthalate are obtained in the form of a brown oil. Optical rotation: [α]D 25= -28.3° (c=2, chloroform).
b) Enantiomer purification of(-)-2-(3,4-dichloro- phenyl)-l-methyl-ethyl-hydrogen-phthalate and decomposition of the semiester
To a solution of 12.19 g (34.51 mmoles) of (-)-2-(3,4-dichloro- phenyl)-l-methyl-ethyl-hydrogen-phthalate {[α]D 25= -28.3° (c=2, chloroform)} and 50 ml of diisopropyl-ether 4.1 g (33.83 mmoles) of (S)-(-)- 1-phenyl-ethyl-amine are added. The two- phase solution is stirred at room temperature overnight. After crystallization the mixture is filtered, washed 3 times with 5 ml of diisopropyl-ether and dried. Thus 8.26 g (17.41 mmoles, 50.5%) of (^>(9-l-ρhenyl-ethyl-ammonium-[(-)-2-(3,4- dichloro-phenyl)-l-memyl-ethyl-phthalate] are obtained.
The crystals obtained are dissolved in 8 ml of hot ethyl-acetate. The solution is allowed to crystallize at -10 0C for 6 hours. The crystals are filtered, washed 5 times with 2.5 ml of diisopropyl- ether each and dried. Thus 6.15 g of (^-^-l-phenyl-ethyl- ammonium-[(-)-2-(3,4-dichloro-phenyl)- 1 -methyl-ethyl- phthalate] are obtained.
The salt is dissolved in 6 ml of hot ethyl-acetate. The solution is allowed to crystallize at -10 0C for 6 hours, filtered, washed 5 times with 2.5 ml of diisopropyl-ether each and dried. Thus 5.56 g (11.72 mmoles, 34.0%) of white crystalline (S)-(-)-l- phenyl-ethyl-ammonium- [(-)-2-(3 ,4-dichloro-phenyl)- 1 - methyl-ethyl-phthalate] are obtained. Optical rotation: [α]D 25= -36.6° (c=l. methanol). [α]D 25= -36.5° (c=2, acetic acid). Mp.: 102-104 0C
To 5.46 g of the salt thus obtained 30 ml of ethyl-acetate are added. The mixture is washed 3 times with 10 ml of 1.5 molar hydrochloric acid each and once with 10 ml of water, dried over sodium sulfate and the solvent is distilled off in vacuo. Thus 3.97 g (11.24 mmoles, 32.6 %) of (-)-2-(3,4-dichloro- phenyl)- 1-methyl-ethyl-hydrogen-phthalate are obtained in the
Figure imgf000055_0001
form of an oil. Optical rotation: [α]D 25= -38.6° (c=2, chloroform).
Mp.: 82-86 0C (after recrystallization from toluol/hexane
90-920C)
A mixture of the (-)-2-(3,4-dichloro-phenyl)-l-methyl-ethyl- hydrogen-phthalate thus obtained, 10 ml of water and 3.0 g of sodium hydroxide is heated to boiling for 1 minute. The reaction mixture is cooled and extracted 4 times with 20 ml of diethyl-ether each. The ethereal phases are united, dried over sodium sulfate and the solvent is distilled off in vacuo. The residual oil (2.04 g) is subjected to distillation in vacuo. Thus 1.85 g (9.02 mmoles, 26.1 %) of (-)-l-(3,4-dichloro-phenyl)-2- propanol are obtained. Optical rotation: [α]D 25= -25.3° (c=2, chloroform). Mp.: 42-46 0C.
Example 10
Resolution of l-(3-bromo-4-methoxy-phenyl)-2-propanol with Pseudomonas cepacia lipase
To a solution of 35.00 g (142.79 mmoles) of l-(3-bromo-4- methoxy-phenyl)-2-propanol and 105 ml of vinyl-acetate 3.00 g of Pseudomonas cepacia lipase (Amano® PS-C) bond to a carrier are added. The reaction mixture is stirred at room temperature for 30 hours, filtered, the enzyme is washed 4 times with 10 ml of vinyl-acetate each and the filtrate is evaporated in vacuo. Thus 39.26 g of a mixture of (+)-l-(3- bromo-4-methoxy-phenyl)-2-propanol and (-)-2-(3-bromo-4- methoxy-phenyl)-l -methyl-ethyl-acetate are obtained in the form of a yellow oil.
The yellow oil thus obtained is dissolved in 100 ml of dichloro-methane, whereupon 12.2 ml (87.65 mmoles, d=0.727) triethyl-amine and in one portion 7.20 g (73,42 mmoles) of maleic anhydride are added. The reaction mixture gradually warms up and its colour turns dark brown. The reaction mixture is heated to boiling for 5 minutes, cooled, washed once with 85 ml and once with 10 ml of a 1.5 molar hydrochloric acid and twice with 15 ml of water. The dichloro- methane phases are extracted once with 100 ml and twice with 5 ml of a 1 molar sodium carbonate solution. The aqueous layers are united and washed 3 times with 15 ml of dichloro- methane each. [The aqueous phase contains the sodium salt of (+)-2-(3~bromo-4-methoxy-phenyl)- 1 -methyl-ethyl-hydrogen- maleate.] The dichloro-methane phases are united, washed over sodium sulfate and the solvent is distilled off in vacuo. Thus 23.54 g (81.98 mmoles, 114.8 %) of (-)-2-(3-bromo-4- methoxy-phenyl)-l -methyl-ethyl-acetate are obtained in the form of a yellow oil. Optical rotation: [α]D 25= -2.9° (c=2, chloroform).
Figure imgf000057_0001
A mixture of 23.34 g of (-)-2-(3-bromo-4-methoxy-phenyl)-l- methyl-ethyl-acetate thus obtained, 15 ml of water, 25 ml of methanol and 5.5 g of sodium hydroxide is heated to boiling for 5 minutes, whereupon the methanol is distilled off in vacuo. The mixture is cooled and extracted 3 times with 25 ml of diethyl-ether each. The ethereal phases are united, dried over sodium sulfate and the solvent is distilled off in vacuo. The residual oil (20.14 g) is subjected to distillation in vacuo. Thus 19.77 g (80.66 mmoles, 113.0 %) of (-)-l-(3-bromo-4- methoxy-phenyl)-2-propanol are obtained in the form of an oil. Optical rotation: [α]D 25= -16.2° (c=2, chloroform).
To the aqueous phase containing the sodium salt of (+)-2-(3- bromo-4-methoxy-phenyl)- 1 -methyl-ethyl-hydrogen-maleate 50 ml of 20 % hydrochloric acid are added and the mixture is extracted once with 50 ml and 3 times with 15 ml of dichloro- methane each. The dichloro-methane phases are united, dried over sodium sulfate and the solvent is distilled off in vacuo. Thus 19.25 g (55.09 mmoles, 78.6 %) of (+)-2-(3-bromo-4- methoxy-phenyl)- 1 -methyl-ethyl-hydrogen-maleate are obtained in the form of yellow oil. Optical rotation: [α]D 25= +9.3° (c=2, chloroform).
Figure imgf000058_0001
A mixture of 19.04 g of (+)-2-(3-bromo-4-methoxy-phenyi)-l- methyl-ethyl-hydrogen-maleate, 60 ml of water and 7 g of sodium hydroxide is heated to boiling for 1 minutes. After cooling the mixture is extracted 4 times with 30 ml of diethyl- ether each. The ethereal phases are united, dried over sodium sulfate and the solvent is distilled off in vacuo. The residual oil (12.56 g) is subjected to distillation in vacuo. Thus 11.86 g (48.39 mmoles, 67.8 %) of (+)-l-(3-bromo-4-methoxy- phenyl)-2-propanol are obtained in the form of an oil. Optical rotation: [α]D 25= +25.4° (c=2, chloroform). On standing the oil solidifies, mp.: 43-46°C.
Example 11
Enantiomer purification of (-)-l-(3-bromo-4-methoxy- phenyl)-2-propanol with the (+)-dehydroabiethyI- ammonium salt of the maleic acid semiester
a) Preparation of(-)-2-(3-bromo-4-methoxy-phenyl)-l- methyl-ethyl-hydrGgen-maleate
A mixture of 10.00 g (40.80 mmoles) of (-)-l-(3-bromo-4- methoxy-phenyl)-2-propanol [α]D 25=: -16.2° (c=2, chloroform), 50 ml of dichloro-methane, 6.30 ml of triethyl-amine (45.26 mmoles) and 4.20 g (42.83 mmoles) of maleic anhydride is heated to boiling for 10 minutes. The reaction mixture is
Figure imgf000059_0001
cooled, washed once with 40 ml, once with 10 ml of 1.5 molar hydrochloric acid and once with 20 ml of water, dried over sodium sulfate and the solvent is distilled off in vacuo. Thus 13.95 g (40.65 mmoles, 99.6 %) of (-)-2-(3-bromo-4-methoxy- phenyl)-l-methyl-ethyl-hydrogen-maleate are obtained in the form of a dark brown oil. Optical rotation: [α]o25=r -6.3° (0=2, chloroform).
b) Enantiomer purification of (-)-2-(3-bromo-4-methoxy- phenyl)-l~methyl-ethyl-hydrogen~maleate and decomposition of the semiester
To a solution of 13.95 g (40.65 mmoles) of (-)-2-(3-bromo-4- methoxy-phenyl)- 1 -methyl-ethyl-hydrogen-maleate { [α]D 25= -6.3° (c=2, chloroform)} in 14 ml of ethyl-acetate 12.0 g (92 %, 38.7 mmoles) of (+)-dehydroabiethyl-amine are added. The clear solution is seeded. The solution is allowed to crystallize for 10 hours. The crystals are filtered, washed 6 times with 5 ml of ethyl-acetate each and dried. Thus 16.02 g (25.77 mmoles, 63,4%) of (+)-dehydroabiethyl-ammonium-[(-)-2-(3- bromo-4-methoxy-phenyl)- 1 -methyl-ethyl-maleate] are obtained.
The salt thus obtained is dissolved in 70 ml of hot acetone. The solution is allowed to crystallize at -10 0C for 2 hours. The crystals are filtered, washed 4 times with 5 ml of ethyl-acetate each and dried. Thus 11.2O g (17.82 mmoles, 43.8%) of (+)- dehydroabiethyl-ammonium-[(-)-2-(3-bromo-4-methoxy- phenyl)-l-methyl-ethyl-maleate] are obtained.
The salt thus obtained is dissolved in 50 ml of hot acetone. The solution is allowed to crystallize at -10 0C for 2 hours. The crystals are filtered, washed 5 times with 5 ml of ethyl-acetate each and dried. Thus 8.36 g (13.30 mmoles, 32.7%) of (+)- dehydroabiethyl-ammonium-[(-)-2-(3-bromo-4-methoxy- phenyl)- 1 -methyl-ethyl— maleate] are obtained. Optical rotation: [α]D 25= +22.0° (c=2, methanol), [α]D 25= +10.9° (c=2, acetic acid). Mp.: 139-141°C.
8.36 g of the salt thus obtained are suspended in 25 ml of methanol, whereupon a solution of 0.70 g of sodium hydroxide in 5 ml of water and 100 ml of water are added. The reaction mixture is extracted 3 times with 30 ml of dichloro-methane each, acidified with 3 ml of 37 % hydrochloric acid and extracted 4 times with 20 ml of dichloro-methane each. The dichloro-methane phases are united, dried over sodium sulfate and the solvent is distilled off in vacuo. Thus 4.33 g (12.62 mmoles, 31.0%) of (-)-2-(3-bromo-4-methoxy-phenyl)-l- methyl-ethyl-hydrogen-maleate are obtained in the form of an oil. Optical rotation: [α]D 25= -8.5° (c=2, chloroform).
Figure imgf000061_0001
A mixture of the (-)-2-(3-bromo-4-methoxy-phenyl)-l-methyl- ethyl-hydrogen-maleate thus obtained, 6 ml of water and 2.O g of sodium hydroxide is heated to boiling for 1 minute. After cooling the mixture is extracted 4 times with 20 ml of diethyl- ether each. The ethereal phases are united, dried over sodium sulfate and the solvent is distilled off in vacuo. The residual crude oil (2.81 g) is subjected to distillation in vacuo. Thus 2.52 g (10.28 mmoles, 25.3 %) of (->l-(3-bromo-4-methoxy- phenyl)-2-propanol are obtained. Optical rotation: [α]D 25= -24.6° (c=2, chloroform). Mp.: 43-46 0C.
Example 12
Resolution of l-(4-fluor-phenyl)-2-propanoI with
Pseudomonas cepacia lipase
To a solution of 5.00 g (32.43 mmoles) of l-(4-fluor-phenyl)- 2-propanol in 25 ml of vinyl-acetate 1.5 g of Pseudomonas cepacia lipase (Amano® PS-C) bond to a carrier are added. The reaction mixture is stirred at room temperature for 15 hours, filtered, the enzyme is washed 4 times with 5 ml of vinyl-acetate each and the filtrate is evaporated in vacuo. Thus 6.26 g of a mixture of a (+)-l-(4-fluor-phenyl)-2-propanol and (-)-2-(4-fluor-phenyl)-l -methyl-ethyl-acetate are obtained in the form of a yellow oil. The oil thus obtained is dissolved in 15 ml of dichloro- methane, whereupon 2.8 ml (20.12 mmoles, d=0.727) of triethyl-amine and in one portion 1.80 g (18.36 mmoles) of maleic anhydride are added. The reaction mixture warms up gradually, while its colour turns dark brown. The reaction mixture is heated to boiling for 5 minutes, cooled, washed once with 45 ml and once with 10 ml of 1.5 molar hydrochloric acid and twice with 10 ml of water each. The dichloro-methane layer is extracted once with 20 ml and twice with 5 ml of 1 molar sodium carbonate solution each. The aqueous layers are united and washed 3 times with 10 ml of dichloro-methane each. [The aqueous phase contains the sodium salt of (+)-2-(4- fluor-phenyl)-l-methyl-ethyl-hydrogen-maleate.] The dichloro- methane phases are united, dried over sodium sulfate and the solvent is distilled off in vacuo. Thus 3.80 g (19.37 mmoles, 119.4 %) of (-)-2-(4-fluor-ρhenyl)-l -methyl-ethyl-acetate are obtained in the form of a yellow oil. Optical rotation: [α]D 25= -4.2° (c=2, chloroform).
A mixture of 3,40 g of (-)-2-(4-fluor-phenyl)-l -methyl-ethyl- acetate, 4 ml of water, 6 ml of methanol and 1.2 g of sodium hydroxide are heated to boiling for 5 minutes, whereupon the methanol is distilled off in vacuo. The reaction mixture is cooled and extracted and 4 times with 10 ml of diethyl-ether each. The ethereal phases are united, dried over sodium sulfate and the solvent is distilled off in vacuo. The residual oil (2.46 g) is distilled off in vacuo. Thus 2.39 g (15.50 mmoles, 95.6 %) of (-)-l-(4-fluor-phenyl)-2-propanol are obtained in the form of an oil . Optical rotation: [α]D 25= -20.5° (c=2, chloroform).
To the aqueous phase containing the sodium salt of (+)-2-(4- fluor-phenyl)-l-methyl-ethyl-hydrogen-maleate 6 ml of 37 % hydrochloric acid are added and the mixture is extracted 4 times with 15 ml of dichloro-methane each. The dichloro- methane phases are united, dried over sodium sulfate and the solvent is distilled off in vacuo. Thus 3.07 g (12.17 mmoles, 75.06 %) of (+)-2-(4-fluor-phenyl)-l -methyl-ethyl -hydrogen- maleate are obtained in the form of a yellow oil. Optical rotation: [α]D 25= +18.5° (c=2, chloroform).
A mixture of '2.67 g of (+)-2-(4-fluor-phenyl)-l-methyl~ethyl- hydrogen-maleate, 4.5 ml of water and 1.5 g of sodium hydroxide is heated to boiling for 1 minute. After cooling the reaction mixture is extracted 4 times with 10 ml of diethyl- ether each. The ethereal phases are united, dried over sodium sulfate and the solvent is distilled off in vacuo. The residual crude oil (1.58 g) is subjected to distillation in vacuo. Thus 1.47 g (9.53 mmoles, 58.8 %) of (+)-l-(4-fluor-phenyl)-2- propanol are obtained. Optical rotation: [α]D 25= +32.2° (c=2, chloroform).

Claims

What we claim is,
1. Compounds of the general Formula
Figure imgf000064_0002
wherein the chiral carbon atom is of (^-configuration
[wherein
R3 is hydrogen;
R and R independently from each other stand for hydrogen, C1-4-alkyl, C1-4-alkoxy, aryloxy, aralkoxy, trifluoromethyl, cyano or halogen; or R and R together form methylenedioxy; with the proviso that at least one of symbols R and R is other than hydrogen; with the proviso that if R1 and R2 stand for alkoxy, one of said substituents is attached to position 2 of the phenyl ring; with the further proviso that if R1 and R2 together form methylenedioxy, said group together with the phenyl ring form l-benzo[l,3]dioxol-4-yl; or if one of symbols R1 and R2 is cyano is attached to position 2, the other group is other than hydrogen or methoxy attached to position 3; or if one of symbols of R1 and R2 is hydrogen, the other is different from methoxy attached to position 2 or 3; or the chiral carbon atom is of (R) -configuration and
Figure imgf000065_0001
R3 is hydrogen;
R1 and R2 independently from each other stand for hydrogen, Ci-4-alkyl, C1-4-alkoxy, aryloxy, aralkoxy, trifiuoromethyl, cyano or halogen; or R and R together form methylenedioxy; with the proviso that at least one of symbols R1 and R2 is other than hydrogen; with the further proviso that if R and R are Ci-4-alkoxy, one of said alkoxy groups is attached to position 2 of the phenyl ring; with the further proviso that if R1 and R2 together form methylenedioxy, said group together with the phenyl ring form l-benzo[l,3]dioxol-4-yl; or if one of symbols R1 and R2 stands for trifluoromethyl attached to position 3 or fluorine attached to position 4, the other symbol is other than hydrogen; or the chiral carbon atom is of (S) -configuration and
Figure imgf000065_0002
R and R independently from each other represent hydrogen, C1-4-alkyl, Ci-4-alkoxy, aryloxy, aralkoxy, trifluoromethyl, cyano or halogen; or R1 and R2 together form methylenedioxy; with the proviso that at least one of symbols R1 and R2 is other than hydrogen; with the further proviso that if R3 is acetyl and at least one of symbols of R and R is hydrogen, the substituent attached to position 4 of the phenyl ring is other than methoxy; or the chiral carbon atom is of (Rj-configuration and R3 is C1-4-acyl;
R1 and R2 independently from each other stand for hydrogen, Ci_4-alkyl, Ci-4-alkoxy, aryloxy, aralkoxy, trifluoromethyl, cyano or halogen; or R1 and R2 together form methylenedioxy; with the proviso that at least one of symbols R1 and R2 is other than hydrogen; with the further proviso that if R3 is acetyl and R1 and R2 together form methylenedioxy, said group together with the phenyl ring form 1 -benzo [1,3] doixole-4-yl; or R3 is acyl in which the group R5 binds said acyl group with a further carboxy group; wherein
R5 stands for substituted or unsubstituted alkenyl or aryl; with the proviso that if R3 stands for phthalyl, one of symbols R1 and R2 represents methoxy attached to position 3 of the phenyl ring and the other is different from hydrogen or methoxy attached to position 4 of the phenyl ring; and salts of said racemic or optically active enantiomers formed with optically active bases with the exception of salts formed with optically active brucine as base and compounds of the general Formula I in which R3 is phthalyl, one of symbols R and R is methoxy attached to position to 3 of the phenyl ring and the other is hydrogen or methoxy attached to position 4 of the phenyl ring.
2. Process for the preparation of enantiomers of aryl- isopropanol derivatives of the general Formula I
(wherein
R3 is hydrogen;
R1 and R2 independently from each other stand for hydrogen, C1-4-alkyl, C1-4-alkoxy, aryloxy, aralkoxy, trifluoromethyl, cyano or halogen; or R1 and R2 together form methylenedioxy) which comprises subjecting the corresponding racemic alcohol of the general
Formula
Figure imgf000067_0001
(wherein R1 and R2 independently from each other stands for hydrogen, Q^-alkyl, Ci-4-alkoxy, aryloxy, aralkoxy, trifluoromethyl, cyano or halogen; or R1 and R2 together form methylenedioxy) to enantioselective acylation in an enzyme catalyzed reaction; thereafter acylating the enantiomeric aryl- isopropanol of the general Formula
Figure imgf000067_0002
which remained unchanged under the conditions of the enzyme-catalyzed reaction (wherein R1 and R2 independently from each other stands for hydrogen, C1-4-alkyl, C1-4-alkoxy, aryloxy, aralkoxy, trifluoromethyl, cyano or halogen; or R1 and R2 together form methylenedioxy) with a dicarboxylic acid derivative in the presence of an acylated enantiomer of the general Formula
Figure imgf000068_0001
R2 formed in the enzyme catalyzed reaction (wherein R4 is Ci-4- alkyl; R1 and R2 independently from each other stands for hydrogen, C1-4-alkyl, Ci-4-alkoxy, aryloxy, aralkoxy, trifluoromethyl, cyano or halogen; or R1 and R2 together form methylenedioxy; with the proviso that at least one of symbols R1 and R2 is other than hydrogen); converting the dicarboxylic acid derivative of the general Formula
Figure imgf000068_0002
(wherein R5 stands for alkyl, branched chain alkyl, alkenyl or aryl; R and R independently from each other stands for hydrogen, C1-4-alkyl, Ci-4-alkoxy, aralkoxy, trifluoromethyl, cyano or halogen; or R1 and R2 together form methylenedioxy) into a salt by using an aqueous base in the presence of a water- insoluble solvent; thereafter separating the aqueous phase which contains the dicarboxylic acid derivative of the general Formula I/D from the organic phase which contains the acylated enantiomeric derivative of the general Formula I/C; thereafter working up both phases by methods known per se to obtain the individual enantiomeric derivatives; and thereafter optionally converting said enantiomeric derivatives into other derivatives and/or purifying the same.
3. Process according to Claim 2 which comprises carrying out the enzyme catalyzing reaction in an acylating solvent or a mixture of an acylating solvent or a further solvent in the presence of a lipase enzyme.
4. Process according to Claim 3 which comprises using as acylating agent vinyl acetate or vinyl butylate, preferably vinyl acetate.
5. Process according to any of Claims 3-4 which comprises using as further solvent an ether type solvent, saturated hydrocarbons, phosphate buffer (pH 7.5); whereby as ether-type solvent preferably diethyl ether; as saturated hydrocarbon preferably hexane or heptane is used.
6. Process according to any of Claims 2-5 which comprises using as lipase enzyme Pseudomonas fluorescens, Pseudomonas cepacia, Candida cylindracea, Candida antarctica and/or Mucor miehei lipase, preferably Pseudomonas cepacia lipase; most preferably Amano® PS-C.
7. Process according to any of Claims 2-5 which comprises carrying out the enzymatic reaction at a temperature between 10-60°C, preferably between 20-400C, most advantageously at room temperature.
8. Process according to any of Claims 2-6 which comprises carrying out the enzymatic reaction for 4-72 hours, preferably 6-48 hours, most advantageously 6-30 hours.
9. Process according to any of Claims 2-8 which comprises using as dicarboxylic acid derivative a derivative of a dicarboxylic acid comprising an alkyl, branched chain alkyl, substituted alkyl, alkenyl, substituted alkenyl or aryl group, preferably an optionally substituted phenyl group.
10. Process according to Claim 9 which comprises using as dicarboxylic acid derivative an acid anhydride.
Figure imgf000071_0001
11. Process according to any of Claims 9 and 10 which comprises using as dicarboxylic acid derivative a maleic acid, succinic acid or phthalic acid derivative.
12. Process according to Claim 2 which comprises carrying out acylation with the dicarboxylic acid derivative in an inert solvent.
13. Process according to Claim 12 which comprises using as inert solvent a chlorinated hydrocarbon, acetonitrile, tetrahydrofurane, preferably dichloromethane.
14. Process according to any of Claims 2, 12 and 13 which comprises using as catalyst an organic base, preferably triethylamine or dimethylamino pyridine.
15. Process according to Claim 2 which comprises using as aqueous base an aqueous solution or suspension of an alkali or alkaline earth metal hydroxide, hydrogen carbonate or carbonate, preferably alkali metal carbonate, most advantageously sodium carbonate.
16. Process according to any of Claims 2-9 which comprises converting an acylated enantiomer derivative of the general Formula I/C (wherein R4 , R1 and R2 are as stated in Claim 2) to the corresponding enantiomeric aryl-isopropanol of the general Formula I/B (wherein R1 and R2 are as stated in Claim 2) by hydrolysis.
17. Process according to Claim 16 which comprises subjecting the enantiomer aryl-isopropanol of the general Formula I/B thus obtained to further purification.
18. Process according to Claim 17 which comprises esterifying in course of purification an enantiomer aryl- isopropanol of the general Formula I/B (wherein R1 and R2 are as stated in Claim 2) with a dicarboxylic acid derivative containing an alkyl, branched chain alkyl, substituted alkyl, alkenyl, substituted alkenyl or aryl group, preferably with a dicarboxylic acid anhydride; forming from the semiester thus obtained a salt with an optically active base; purifying the salt thus obtained by fractionated crystallization; optionally setting free the base from the pure salt thus obtained; optionally subjecting the enantiomer pure semiester of the general Formula I/D thus obtained (wherein R5, R1 and R2 are as stated in Claim 2) to hydrolysis; and recovering the enantiomer pure phenyl isopropyl alcohol derivative of the general Formula I/B thus obtained (wherein R1 and R2 are as stated in Claim 2) from the reaction mixture by methods known per se.
19. Process according to Claim 18 which comprises subjecting the salt of a dicarboxylic acid semiester derivative of the general Formula IfD formed with an optically active base to fractionated recrystallization from an inert solvent.
20. Process according to Claim 19 which comprises using as inert solvent a dipolar aprotic solvent or an ether type solvent, preferably ethyl acetate, acetone, diisopropyl ether, diethyl ether or a mixture thereof.
21. Process according to Claim 19 which comprises using as optically active base (Rj-(+)-l-phenyl-ethyl-amine, (S)-(-)- 1-phenyl-ethyl-amine, (+)-dehydroabiethyl-amine, quinine, (-)- l-(4-nitrophenyl)-2-amino- 1,3 -propanediol or (S)-(+)-2- benzyl-amino- 1 -butanol.
22. (±)-, (-)-, and (+)-2-(l-benzo[l,3]dioxol-5-yl)-l-methyl- ethyl-hydrogen-maleate.
23. (±)-, (-)-, and (+)-2-(l-benzo[l,3]dioxol-5-yl)-l-methyl- ethyl-hydrogen-succinate.
24. (±)-, (-)-, and (+)-2-(l-benzo[l,3]dioxol-5-yl)-l-methyl- ethyl-hydrogen-phthalate.
25. (^)-(-)-phenyl-ethyl-ammonium-{(+)-2-(l - benzo[l,3]dioxol-5-yl)-l-methyl-ethyl-maleate} .
26. (2?;-f+;-phenyl-ethyl-aπunonium- {(+)-2-(l - benzo [ 1 ,3] dioxol-5-yl)- 1 -methyl-ethyl-maleate} ,
27. (^-(9-phenyl-ethyl-ammonium- {(-)-2-(l - benzo[ 1 ,3]dioxol-5-yl)- 1 -methyl-ethyl-maleate} ,
28. (Rj-f+j-phenyl-ethyl-ammonium- {(-)-2-(l- benzo[l,3]dioxol-5-yl)-l-methyl-ethyl-maleate},
29. (+)-dehydroabiethyl-ammonium- {(-)-2-(l - benzo[ 1 ,3]dioxol-5-yl)- 1 -methyl-ethyl-maleate} .
30. (±)-, (-)-, and (+)-2-(4-chloro-phenyl)- 1 -methyl-ethyl- hydrogen-maleate.
31. (±)-, (-)-, and (+)-2-(4-chloro-phenyl)-l-methyl-ethyl- hydrogen-succinate.
32. (±)-, (-)-, and (+)-2-(4-chloro-phenyl)- 1 -methyl-ethyl- hydrogen-phthalate.
33. (-)-2-(4-chloro-phenyl)- 1 -methyl-ethyl-acetate.
34. (+)- and (-)-l-(4-chloro-phenyl)-2-propanol.
35. (^-(+)-phenyl-ethyl-ammonium-[(-)-2-(4-chloro- phenyl)- 1 -methyl-ethyl-succinate] .
36. f'S/)-f-y)-phenyl-ethyl-aπimonium-[(-)-2-(4-chloro- phenyl)- 1 -methyl-ethyl-succinate] ,
37. fRj-f'+)-phenyl-ethyl-ammonium-[(+)-2-(4-chloro- phenyl)- 1 -methyl-ethyl-maleate],
38. (/S>(9-phenyl-ethyl-ammonium-[(+)-2-(4-chloro- phenyl)- 1 -methyl-ethyl-maleate],
39. (+)-dehydroabiethyl-ammonium- [(+)-2-(4-chloro- phenyl)-l-methyl-ethyl-maleate],
40. (+)-dehydroabiethyl- ammonium- [(-)-2-(4-chloro- phenyl)- 1 -methyl-ethyl-maleate],
41. (2?j-f+/)-phenyl-ethyl-ammonium-[(-)-2-(4-chloro- phenyl)- 1 -methyl-ethyl-phthalate],
Figure imgf000076_0001
42. (/Sj-f'--//)-phenyl-ethyl-aminonium-[(-)-2-(4-chloro- phenyl)- 1 -methyl-ethyl-phthalate] ,
43. (^-(^-phenyl-ethyl-animonium-[(-)-2-(4-chloro- phenyl)-l-methyl-ethyl-maleate],
44. (+)-2-(4-chloro-phenyl)- 1 -methyl-ethyl-hydrogen- succinate quinine salt.
45. (-)-2-hydroxy- 1 -(hydroxy-methyl)-2-(4-nitro-phenyl)- emyl-ammonium-[(+)-2-(4-chloro-phenyl)- 1 -methyl-ethyl- phthalate].
46. (±)-, (-)-, and (+)-2-(3-chloro-phenyl)-l-methyl-ethyl- hydrogen-maleate .
47. (±>, (-)-, and (+)-2-(3-chloro-ρhenyl)-l-methyl-ethyl- hydrogen-succinate.
48. (±)-, (-)-, and (+)-2-(3-chloro-phenyl> 1 -methyl-ethyl- hydrogen-phthalate.
49. (-)-2-(3-chloro-phenyl)- 1 -methyl-ethyl-acetate.
50. (+)- and (-)- 1 -(3 -chloro-phenyl)-2-propanol.
Figure imgf000077_0001
51. (+)-dehydroabiethyl-ammonium-[(+)-2-(3-chloro- phenyl)- 1 -methyl-ethyl-maleate] .
52. (+)-dehydroabiethyl-ammonium- [(-)-2-(3 -chloro- phenyl)- 1 -methyl-ethyl— maleate] .
53. f2?j-(+)-ρhenyl-ethyl-ammonium-[(-)-2-(3-chloro- phenyl)- 1 -methyl-ethyl-maleate] .
54. ($-(-)-phenyl-ethyl-ammomum- [(-)-2-(3 ,4-dichloro- phenyl)- 1 -methyl-ethyl-phtalate] .
55. (±)-, (-)-, and (+)-2-(3,4-dichloro-phenyl)-l-methyl- ethyl-hydrogen-maleate.
56. (±)-, (-)-, and (+)-2-(3,4-dichloro-ρhenyl)-l-methyl- ethyl-hydrogen-succinate.
57. (±)-, (-)-, and (+)-2-(3,4-dichloro-phenyl)-l-methyl- ethyl-hydrogen-phthalate.
58. (-)-2-(3,4-dichloro-ρhenyl)-l-methyl-ethyl-acetate.
59. (+)- and (-)-l-(354-dichloro-phenyl)-2-propanol.
Figure imgf000078_0001
60. fi?j-(4-)-ρhenyl-etliyi-ammonium- [(-)-2-(3 ,4-dichloro- phenyl)- 1 -methyl-ethyl-maleate] .
61. (R>(+)-ρhenyl-ethyl-ammonium- [(+)-2-(3 ,4-dichloro- phenyl)- 1 -methyl-ethyl-phthalate] .
62. (^-(9-phenyl-ethyl-ammonium-[(-)-2-(3,4-dichloro- phenyl)- 1 -methyl-ethyl-succinate]
63. (+)-dehydroabiethyl-ammonium-[(+)-2-(3 ,4-dichloro- phenyl)- 1 -methyl-ethyl-maleate] .
64. (+)-dehydroabiethyl-ammonium- [(+)-2-(3 ,4-dichloro- phenyl)- 1 -mefhyl-ethyi-succinate]
65. (±)-, (-)-, and (+)-2-(3-bromo-4-methoxy-phenyl)-l- methyl-ethyl-hydrogen-maleate.
66. (±)-5 (-)-, and (+)-2-(3-bromo-4-methoxy-phenyl)-l- methyl-ethyl-hydrogen-succinate.
67. (±)-5 (-)-, and (+)-2-(3-bromo-4-methoxy-ρhenyl)-l- methyl-ethyl-hydrogen-phthalate.
68. (-)-2-(3 -bromo-4-methoxy-phenyl)- 1 -methyl-ethyl- acetate.
69. (+)- and (-)-l-(3-bromo-4-methoxy-phenyl)-2-propanol.
70. (+)-dehydroabiethyl-aτnmoniυ.m-[(-)-2-(3-bromo-4- methoxy-phenyl)- 1 -methyl-ethyl-maleate] .
71. fKJ-(+)-ρhenyl-ethyl-ammonmm-[(+)-2-(3-bromo-4- methoxy-phenyl)- 1-methyl-ethyl-succinate] .
72. (2?>(+)-phenyl-ethyl-ammonium-[(-)-2-(3-bromo-4- methoxy-phenyl)- 1 -methyl-ethyl-phthalate] .
73. (5H+)-benzyl-[ 1 -(hydroxy-methyl)-proρyl]- ammonium- [(-)-2-(3 -bromo-4-methoxy-phenyl)- 1 -methyl- ethyl-phthalate] .
74. (±)-, (-)-, and (+)-2-(4-fliαoto-phenyl)-l-methyl-ethyl- hydrogen-maleate.
75. (±)-, (-)-, and (+)-2-(4-fhioro-phenyl)- 1 -methyl-ethyl- hydrogen-succinate.
76. (±)-, (-)-, and (+)-2-(4-fluoro-phenyl)- 1 -methyl-ethyl- hydrogen-phthalate.
77. (-)-2-(4-fluoro-phenyl)- 1 -methyl-ethyl-acetate.
78. (+)- 1 -(4-fluoro-phenyl)-2-propanol.
PCT/HU2005/000067 2004-06-23 2005-06-23 Pharmaceutical intermediates and a process for the preparation thereof WO2006013399A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
HU0401267A HU0401267D0 (en) 2004-06-23 2004-06-23 New intermediates and process for producing them
HUP0401267 2004-06-23
HUP0500622 2005-06-22
HU0500622A HUP0500622A3 (en) 2005-06-22 2005-06-22 New intermediates and process for producing them

Publications (1)

Publication Number Publication Date
WO2006013399A1 true WO2006013399A1 (en) 2006-02-09

Family

ID=89986097

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HU2005/000067 WO2006013399A1 (en) 2004-06-23 2005-06-23 Pharmaceutical intermediates and a process for the preparation thereof

Country Status (1)

Country Link
WO (1) WO2006013399A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2258696A1 (en) * 2009-05-14 2010-12-08 ENDURA S.p.A. Process for preparing enriched enantiomers of 3-(Benzo[1,3]dioxol-5-yl)-2-methylpropanal
CN106478588A (en) * 2016-09-04 2017-03-08 王际菊 A kind of chiral 1 piperonyl 2 propanol and its isomery preparation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312950A (en) * 1993-08-31 1994-05-17 Eastman Kodak Company Method for purification of alcohols
WO2005044801A1 (en) * 2003-10-31 2005-05-19 Astrazeneca Ab Pyridine carboxylic acid derivatives as glucokinase modulators

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312950A (en) * 1993-08-31 1994-05-17 Eastman Kodak Company Method for purification of alcohols
WO2005044801A1 (en) * 2003-10-31 2005-05-19 Astrazeneca Ab Pyridine carboxylic acid derivatives as glucokinase modulators

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
A. CORDOVA ET AL.: "A Sequential Application of Kinetic Resolution and Polymer-Supported Scavenging for the Isolation of Chiral Secondary Alcohols", J. ORG. CHEM., vol. 66, no. 16, 2001, pages 5645 - 5648, XP002354711 *
BIANCHI, DANIELE ET AL: "Anhydrides as Acylating Agents in Lipase-Catalyzed Stereoselective Esterification of Racemic Alcohols", JOURNAL OF ORGANIC CHEMISTRY, vol. 53, no. 23, 1988, pages 5531 - 5534, XP002354710 *
D. KALIAKOUDAS ET AL.: "4. Synthese von Plectranthonen, diterpenoiden Phenanthren-1,4-chinonen", HELV. CHIM. ACTA, vol. 73, no. 1, 1990, pages 48 - 62, XP009057164 *
D'ANTONA, NICOLA ET AL: "Effective enzymatic resolution of rac-1-(3-trifluoromethylphenyl)propan-2- ol, precursor of fenfluramine", CHIRALITY, vol. 14, no. 4, 2002, pages 325 - 328, XP002354707 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SANDERS, WILLIAM J. ET AL: "Synthesis of (+)-(R)-6-ethyl-2,3-dihydro-2-methyl-4H-pyran-4-one-sex pheromone component of the male swift moth Hepialus hecta L", XP002354933, retrieved from STN Database accession no. 1993:254580 *
DATABASE CROSSFIRE BEILSTEIN Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main (DE); XP002354932, Database accession no. BRN 7804275 *
G. FRONZA ET AL.: "On the Mode of Baker's Yeast Transformation of 3-Chloropropiophenone and Related Ketones. Synthesis of (2S)-[2-2H]Propiophenone, (R)-Fluoxetine, and (R)- and (S)-Fenfluramine", J. ORG. CHEM., vol. 56, no. 21, 1991, pages 6019 - 6023, XP002354703 *
GIRIJAVALLABHAN, V. M. ET AL: "Synthesis of the antifungal agent SCH 42427 (SM 9164)", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 1, no. 7, 1991, pages 349 - 352, XP002354706 *
GUTMAN, ARIE L. ET AL: "Convenient practical resolution of racemic alkyl-aryl alcohols via enzymic acylation with succinic anhydride in organic solvents", TETRAHEDRON: ASYMMETRY, vol. 4, no. 5, 1993, pages 839 - 844, XP002354709 *
JUVANCZ, ZOLTAN ET AL: "Copolymeric (1R-trans)-N,N'-1,2-cyclohexylene-bisbenzamide oligodimethylsiloxane chiral stationary phase for gas chromatography", JOURNAL OF CHROMATOGRAPHY, A, vol. 982, no. 1, 2002, pages 119 - 126, XP002354704 *
P. FERRABOSCHI ET AL.: "Baker's Yeast-mediated Preparation of Optically Actice Aryl Alcohols and Diols for the Synthesis of Chiral Hydroxy Acids", J. CHEM. SOC. PERKIN TRANS. 1, 1990, pages 2469 - 2474, XP009057167 *
R. H. PICKARD AND J. KENYON: "CVII.- Investigations on the Dependence or Rotatory Power on Chemical Constitution. Part. VI. The optical Rotatory Power of Methyl-tert.-butyl, Methylbenzyl-, Methylphenylethyl- and Methyl-.alpha.nyphthyl-carbinols", J. CHEM. SOC., 1914, pages 1115 - 1131, XP009057144 *
SCHUBERT, THOMAS ET AL: "Chemoenzymic synthesis of (S)-8-O-Methylmellein by Candida parapsilosis carbonyl reductase", SYNTHESIS, no. 12, 1999, pages 2045 - 2048, XP002354705 *
SYNTHETIC COMMUNICATIONS, vol. 23, no. 1, 1993, pages 87 - 95 *
T. WIRTH; G. FRAGALE, CHEM. EUROP. J., vol. 3, no. 11, 1997, pages 1894 - 1902 *
TADASHI EMA ET AL.: "Mechanism-based enzymatic method for reliable determination of absolute configuration of chiral 1-substituted ethanols: combination with NMR method", TETRAHEDRON: ASYMMETRY, vol. 13, no. 11, 2002, pages 1223 - 1230, XP004371736 *
WAGNER J M ET AL: "Stereospecific synthesis of amphetamines", TETRAHEDRON: ASYMMETRY, vol. 14, no. 15, 1 August 2003 (2003-08-01), pages 2119 - 2125, XP004441345, ISSN: 0957-4166 *
WALLNER, SABINE R. ET AL: "Highly enantioselective stereo-inverting sec-alkylsulfatase activity of hyperthermophilic Archaea", ORGANIC & BIOMOLECULAR CHEMISTRY, vol. 3, no. 14, 2005, pages 2652 - 2656, XP002354708 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2258696A1 (en) * 2009-05-14 2010-12-08 ENDURA S.p.A. Process for preparing enriched enantiomers of 3-(Benzo[1,3]dioxol-5-yl)-2-methylpropanal
CN106478588A (en) * 2016-09-04 2017-03-08 王际菊 A kind of chiral 1 piperonyl 2 propanol and its isomery preparation

Similar Documents

Publication Publication Date Title
EP2297090A1 (en) Stereoselective enzymatic synthesis of (s) or (r)-iso-butyl-glutaric ester
CA2660917C (en) Process for producing benzoxazine derivative and production intermediate thereof
RU2124506C1 (en) Method of stereoselective synthesis of heterobicyclic alcohol enantiomer, pure alcohol enantiomer, method of synthesis of piperazine derivative
CH682488A5 (en) Process for preparing derivatives furo (3,4-c) pyridine in non-racemic form.
CA2161849A1 (en) Production of optically active compounds
WO2006013399A1 (en) Pharmaceutical intermediates and a process for the preparation thereof
JP2007519655A (en) Process for the preparation of enantiomerically pure amino alcohols
JP3781788B2 (en) Method for producing optically active ester of trans-3-phenylglycidic acid and method for producing benzo (thi) azepine
EP2218788B1 (en) Process for the preparation of optically active cyclopentenones
US4865771A (en) Process for preparing L(-)-carnitine chloride from 3,4-epoxybutyric esters and novel intermediate compounds
EP1733042B1 (en) Chemo-enzymatic process for preparing escitalopram
JP2001514901A (en) Biochemical racemic resolution of cis- and trans-pyrrolopiperidine
JPH0533995B2 (en)
JP5329973B2 (en) From racemic 4- (1-aminoethyl) benzoic acid methyl ester to (R)-and (S) -4- (1-ammoniumethyl) by enantioselective acylation using a lipase catalyst followed by precipitation with sulfuric acid. Method for preparing benzoic acid methyl ester sulfate
EP0718407B1 (en) Intermediates for the synthesis of eliprodil enantiomers and process for their preparation
JP2008507487A (en) Process for the preparation of (2R, 3R) -2-hydroxy-3-amino-3-aryl-propionamide and (2R, 3R) -2-hydroxy-3-amino-3-aryl-propionic acid alkyl esters
JPH08113550A (en) Production of optically active 3-hydroxyhexanoic acids
RU2258069C2 (en) Methods for preparing benzoxazine derivative, methods for preparing its intermediate compound and intermediate compounds
WO2006059347A2 (en) Improved process for preparation of ramipril
CN1101378A (en) Enzymatic process for the stereoselective preparation of a hetero-bicyclic alcohol enantiomer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase